# Combination of active substances with insecticidal properties

The invention relates to novel insecticidal active compound combinations consisting, firstly, of known anthranilamides and, secondly, of further known insecticidally active compounds, which combinations are highly suitable for controlling animal pests, such as insects.

It is already known that certain anthranilamides have insecticidal properties (WO 01/70671, WO 02/094791, WO 03/015519, WO 03/016284, WO 03/015518, WO 03/024222, WO 03/016282, WO 03/016283, WO 03/062226, WO 03/027099).

The generic formulae and definitions described in these publications and the individual compounds described therein are expressly incorporated herein by way of reference.

Furthermore, it is already known that numerous heterocycles, organotin compounds, benzoylureas and pyrethroids have insecticidal and acaricidal properties (cf. WO 93/22297, WO 93/10083, DE-A 26 41 343, EP-A 347 488, EP-A 210 487, US 3,364,177 and EP-A 234 045). However, the activity of these compounds is likewise not always satisfactory.

It has now been found that mixtures of anthranilamides of the formula (I)

in which

 $R^1$ 

25

10

15

A<sup>1</sup> and A<sup>2</sup> independently of one another represent oxygen or sulfur,

20 X<sup>1</sup> represents N or CR<sup>10</sup>,

represents hydrogen or represents in each case optionally mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, where the substituents independently of one another may be selected from the group consisting of R<sup>6</sup>, halogen, cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>2</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>4</sub>-alkyl)C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino and R<sup>11</sup>,

10

15

20

25

30

35

R<sup>2</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, C<sub>2</sub>-C<sub>6</sub>-alkoxy-carbonyl or C<sub>2</sub>-C<sub>6</sub>-alkylcarbonyl,

represents hydrogen, R<sup>11</sup> or represents in each case optionally mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, where the substituents independently of one another may be selected from the group consisting of R<sup>6</sup>, halogen, cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl, R<sup>11</sup>, phenyl, phenoxy and a 5- or 6-membered heteroaromatic ring, where each phenyl, phenoxy and 5- or 6-membered heteroaromatic ring may optionally be substituted and where the substituents independently of one another may be selected from one to three radicals W or one or more radicals R<sup>12</sup>, or

 $R^2$  and  $R^3$  may be attached to one another and form the ring M,

represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>2</sub>-C<sub>6</sub>-haloalkenyl, C<sub>2</sub>-C<sub>6</sub>-haloalkynyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, halogen, cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl or represents in each case optionally mono- or polysubstituted phenyl, benzyl or phenoxy, where the substituents independently of one another may be selected from the group consisting of C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>2</sub>-C<sub>4</sub>-haloalkenyl, C<sub>2</sub>-C<sub>4</sub>-haloalkynyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, halogen, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, C<sub>3</sub>-C<sub>6</sub>-(alkyl)cycloalkylamino, C<sub>2</sub>-C<sub>4</sub>-alkylcarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylaminocarbonyl, C<sub>3</sub>-C<sub>8</sub>-dialkylaminocarbonyl and C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl,

R<sup>5</sup> and R<sup>8</sup> in each case independently of one another represent hydrogen, halogen or represent in each case optionally substituted C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, R<sup>12</sup>, G, J, -OJ, -OG, -S(O)<sub>p</sub>-J, -S(O)<sub>p</sub>-G, -S(O)<sub>p</sub>-phenyl, where the substituents independently of one another may be selected from one to three radicals W or from the group consisting of R<sup>12</sup>, C<sub>1</sub>-C<sub>10</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy and C<sub>1</sub>-C<sub>4</sub>-alkythio, where each substituent may be substituted by one or more substituents independently of one another selected from the group consisting of G, J, R<sup>6</sup>, halogen, cyano, nitro, amino, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl, phenyl and phenoxy, where each phenyl or phenoxy ring

10

20

.25

may optionally be substituted and where the substituents independently of one another may be selected from one to three radicals W or one or more radicals R<sup>12</sup>,

- in each case independently of one another represent a 5- or 6-membered nonaromatic carbocyclic or heterocyclic ring which optionally contains one or two ring members from the group consisting of C(=O), SO and S(=O)<sub>2</sub> and which may optionally be substituted by one to four substituents independently of one another selected from the group consisting of C<sub>1</sub>-C<sub>2</sub>-alkyl, halogen, cyano, nitro and C<sub>1</sub>-C<sub>2</sub>-alkoxy, or independently of one another represent C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl, C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, (cyano)C<sub>3</sub>-C<sub>7</sub>-cycloalkyl, (C<sub>1</sub>-C<sub>4</sub>-alkyl)C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, (C<sub>3</sub>-C<sub>6</sub>-cycloalkyl)C<sub>1</sub>-C<sub>4</sub>-alkyl, where each cycloalkyl, (alkyl)cycloalkyl and (cycloalkyl)alkyl may optionally be substituted by one or more halogen atoms,
- J in each case independently of one another represent an optionally substituted 5- or 6membered heteroaromatic ring, where the substituents independently of one another may be selected from one to three radicals W or one or more radicals R<sup>12</sup>.
- independently of one another represent -C(=E<sup>1</sup>)R<sup>19</sup>, -LC(=E<sup>1</sup>)R<sup>19</sup>, -C(=E<sup>1</sup>)LR<sup>19</sup>, -C(=E<sup>1</sup>)LR<sup>19</sup>, -C(=E<sup>1</sup>)LR<sup>19</sup>, -OP(=Q)(OR<sup>19</sup>)<sub>2</sub>, -SO<sub>2</sub>LR<sup>18</sup> or -LSO<sub>2</sub>LR<sup>19</sup>, where each E<sup>1</sup> independently of the others represents O, S, N-R<sup>15</sup>, N-OR<sup>15</sup>, N-N(R<sup>15</sup>)<sub>2</sub>, N-S=O, N-CN or N-NO<sub>2</sub>,
  - R<sup>7</sup> represents hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, halogen, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfonyl,
  - R<sup>9</sup> represents C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl or halogen,
  - R<sup>10</sup> represents hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, halogen, cyano or C<sub>1</sub>-C<sub>4</sub>-haloalkoxy,
  - in each case independently of one another represent in each case optionally monoto trisubstituted C<sub>1</sub>-C<sub>6</sub>-alkylthio, C<sub>1</sub>-C<sub>6</sub>-alkylsulfenyl, C<sub>1</sub>-C<sub>6</sub>-haloalkythio, C<sub>1</sub>-C<sub>6</sub>-haloalkylsulfenyl, phenylthio or phenylsulfenyl, where the substituents independently of one another may be selected from the list consisting of W, -S(O)<sub>n</sub>N(R<sup>16</sup>)<sub>2</sub>, -C(=O)R<sup>13</sup>, -L(C=O)R<sup>14</sup>, -S(C=O)LR<sup>14</sup>, -C(=O)LR<sup>13</sup>, -S(O)<sub>n</sub>NR<sup>13</sup>C(=O)R<sup>13</sup>, -S(O)<sub>n</sub>NR<sup>13</sup>C(=O)LR<sup>14</sup> and -S(O)<sub>n</sub>NR<sup>13</sup>S(O)<sub>2</sub>LR<sup>14</sup>,
  - L in each case independently of one another represent O, NR<sup>18</sup> or S,
- 30  $R^{12}$  in each case independently of one another represent -B(OR<sup>17</sup>)<sub>2</sub>, amino, SH, thiocyanato, C<sub>3</sub>-C<sub>8</sub>-trialkylsilyloxy, C<sub>1</sub>-C<sub>4</sub>-alkyl disulfide, -SF<sub>5</sub>, -C(=E)R<sup>19</sup>, -LC(=E)R<sup>19</sup>, -C(=E)LR<sup>19</sup>, -LC(=E)LR<sup>19</sup>, -OP(=Q)(OR<sup>19</sup>)<sub>2</sub>, -SO<sub>2</sub>LR<sup>19</sup> or -LSO<sub>2</sub>LR<sup>19</sup>,
  - Q represents O or S,
- in each case independently of one another represent hydrogen or represent in each case optionally mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>2</sub>-C<sub>6</sub>-alkenyl, C<sub>2</sub>-C<sub>6</sub>-alkynyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, where the substituents independently of one another may be selected from the

10

15

20

25

30

35

R19

group consisting of  $R^6$ , halogen, cyano, nitro, hydroxyl,  $C_1$ - $C_4$ -alkylsulfinyl,  $C_1$ - $C_4$ -alkylsulfonyl,  $C_1$ - $C_4$ -alkylsulfonyl,  $C_1$ - $C_4$ -alkylamino,  $C_2$ - $C_8$ -dialkylamino,  $C_3$ - $C_6$ -cycloalkylamino and  $(C_1$ - $C_4$ -alkyl) $C_3$ - $C_6$ -cycloalkylamino,

R<sup>14</sup> in each case independently of one another represent in each case mono- or polysubstituted C<sub>1</sub>-C<sub>20</sub>-alkyl, C<sub>2</sub>-C<sub>20</sub>-alkenyl, C<sub>2</sub>-C<sub>20</sub>-alkynyl or C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, where the substituents independently of one another may be selected from the group consisting of R<sup>6</sup>, halogen, cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino and (C<sub>1</sub>-C<sub>4</sub>-alkyl)C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino or represent optionally substituted phenyl, where the substituents independently of one another may be selected from one to three radicals W or one or more radicals R<sup>12</sup>,

in each case independently of one another represent hydrogen or represent in each case mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>-haloalkyl or C<sub>1</sub>-C<sub>6</sub>-alkyl, where the substituents independently of one another may be selected from the group consisting of cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylthio, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl and optionally substituted phenyl, where the substituents independently of one another may be selected from one to three radicals W or one or more radicals R<sup>12</sup>, or N(R<sup>15</sup>)<sub>2</sub> represents a cycle which forms the ring M,

 $R^{16}$  represents  $C_1$ - $C_{12}$ -alkyl or  $C_1$ - $C_{12}$ -haloalkyl, or  $N(R^{16})_2$  represents a cycle which forms the ring M,

R<sup>17</sup> in each case independently of one another represent hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl, or B(OR<sup>17</sup>)<sub>2</sub> represents a ring, where the two oxygen atoms are attached via a chain to two or three carbon atoms which are optionally substituted by one or two substituents independently of one another selected from the group consisting of methyl and C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl,

 $R^{18}$  in each case independently of one another represent hydrogen,  $C_1$ - $C_6$ -alkyl or  $C_1$ - $C_6$ -haloalkyl, or  $N(R^{13})(R^{18})$  represents a cycle which forms the ring M,

in each case independently of one another represent hydrogen or represent in each case optionally mono- or polysubstituted C<sub>1</sub>-C<sub>6</sub>-alkyl, where the substituents independently of one another may be selected from the group consisting of cyano, nitro, hydroxyl, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylthio, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, CO<sub>2</sub>H, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylcarbonyl, C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl and optionally substituted phenyl, where the substituents independently of one another may be selected from one to three radicals W, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl or phenyl or

10

20

pyridyl, each of which is optionally mono- to trisubstituted by W,

- in each case represents an optionally mono- to tetrasubstituted ring which, in addition to the nitrogen atom which is attached to the substituent pair R<sup>13</sup> and R<sup>18</sup>, (R<sup>15</sup>)<sub>2</sub> or (R<sup>16</sup>)<sub>2</sub>, contains two to six carbon atoms and optionally additionally a further nitrogen, sulfur or oxygen atom, and where the substituents independently of one another may be selected from the group consisting of C<sub>1</sub>-C<sub>2</sub>-alkyl, halogen, cyano, nitro and C<sub>1</sub>-C<sub>2</sub>-alkoxy,
- win each case independently of one another represent C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>2</sub>-C<sub>4</sub>-alkenyl, C<sub>2</sub>-C<sub>4</sub>-alkynyl, C<sub>3</sub>-C<sub>6</sub>-cycloalkyl, C<sub>1</sub>-C<sub>4</sub>-haloalkyl, C<sub>2</sub>-C<sub>4</sub>-haloalkenyl, C<sub>2</sub>-C<sub>4</sub>-haloalkynyl, C<sub>3</sub>-C<sub>6</sub>-halocycloalkyl, halogen, cyano, nitro, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylthio, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-alkylamino, C<sub>2</sub>-C<sub>8</sub>-dialkylamino, C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, (C<sub>1</sub>-C<sub>4</sub>-alkyl)C<sub>3</sub>-C<sub>6</sub>-cycloalkylamino, C<sub>2</sub>-C<sub>4</sub>-alkylcarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkoxy-carbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylaminocarbonyl, C<sub>3</sub>-C<sub>8</sub>-dialkylaminocarbonyl or C<sub>3</sub>-C<sub>6</sub>-trialkylsilyl,
- n in each case independently of one another represent 0 or 1,
- 15 p in each case independently of one another represent 0, 1 or 2,

where in the case that (a) R<sup>5</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>2</sub>-C<sub>6</sub>-haloalkenyl, C<sub>2</sub>-C<sub>6</sub>-haloalkynyl, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkylthio or halogen and (b) R<sup>8</sup> represents hydrogen, C<sub>1</sub>-C<sub>6</sub>-alkyl, C<sub>1</sub>-C<sub>6</sub>-haloalkyl, C<sub>2</sub>-C<sub>6</sub>-haloalkenyl, C<sub>2</sub>-C<sub>6</sub>-haloalkynyl, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkylthio, halogen, C<sub>2</sub>-C<sub>4</sub>-alkylcarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylaminocarbonyl or C<sub>3</sub>-C<sub>8</sub> dialkylaminocarbonyl, (c) at least one substituent selected from the group consisting of R<sup>6</sup>, R<sup>11</sup> and R<sup>12</sup> is present and (d), if R<sup>12</sup> is not present, at least one R<sup>6</sup> or R<sup>11</sup> is different from C<sub>2</sub>-C<sub>6</sub>-alkylaminocarbonyl, C<sub>2</sub>-C<sub>6</sub> alkoxycarbonyl, C<sub>2</sub>-C<sub>6</sub>-alkylaminocarbonyl and C<sub>3</sub>-C<sub>8</sub>-dialkylaminocarbonyl, and

25 the compounds of the general formula (I) also include N-oxides and salts,

and at least one active compound from the group of the pyrethroids (active compounds of group 2) is synergistically effective and suitable for controlling animal pests.

Depending inter alia on the nature of the substituents, the compounds of the formula (I) may be present as geometrical and/or optical isomers or isomer mixtures of varying composition which, if appropriate, may be separated in a customary manner. The present invention provides both the pure isomers and the isomer mixtures, their preparation and use and also compositions comprising them. However, hereinbelow, for the sake of simplicity, only compounds of the formula (I) are referred to, although what is meant are both the pure compounds and, if appropriate, also mixtures having varying proportions of isomeric compounds.

Preference is given to active compound combinations comprising compounds of the formula (I-1)

#### 5 in which

25

- R<sup>2</sup> represents hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl,
- R<sup>3</sup> represents C<sub>1</sub>-C<sub>6</sub>-alkyl which is optionally substituted by a radical R<sup>6</sup>,
- R<sup>4</sup> represents C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>2</sub>-haloalkyl, C<sub>1</sub>-C<sub>2</sub>-haloalkoxy or halogen,
- R<sup>5</sup> represents hydrogen, C<sub>1</sub>-C<sub>4</sub>-alkyl, C<sub>1</sub>-C<sub>2</sub>-haloalkyl, C<sub>1</sub>-C<sub>2</sub>-haloalkoxy or halogen,
- represents -C(=E<sup>2</sup>)R<sup>19</sup>, -LC(=E<sup>2</sup>)R<sup>19</sup>, -C(=E<sup>2</sup>)LR<sup>19</sup> or -LC(=E<sup>2</sup>)LR<sup>19</sup>, where each E<sup>2</sup> independently of the others represents O, S, N-R<sup>15</sup>, N-OR<sup>15</sup>, N-N(R<sup>15</sup>)<sub>2</sub>, and each L independently of the others represents O or NR<sup>18</sup>,
  - R<sup>7</sup> represents C<sub>1</sub>-C<sub>4</sub>-haloalkyl or halogen,
  - R<sup>9</sup> represents C<sub>1</sub>-C<sub>2</sub>-haloalkyl, C<sub>1</sub>-C<sub>2</sub>-haloalkoxy, S(O)<sub>p</sub>C<sub>1</sub>-C<sub>2</sub>-haloalkyl or halogen,
- in each case independently of one another represent hydrogen or represent in each case optionally substituted C<sub>1</sub>-C<sub>6</sub>-haloalkyl or C<sub>1</sub>-C<sub>6</sub>-alkyl, where the substituent independently of one another may be selected from the group consisting of cyano, C<sub>1</sub>-C<sub>4</sub>-alkoxy, C<sub>1</sub>-C<sub>4</sub>-haloalkoxy, C<sub>1</sub>-C<sub>4</sub>-alkylsulfinyl, C<sub>1</sub>-C<sub>4</sub>-alkylsulfonyl, C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfinyl or C<sub>1</sub>-C<sub>4</sub>-haloalkylsulfonyl,
- 20 R<sup>18</sup> in each case represents hydrogen or C<sub>1</sub>-C<sub>4</sub>-alkyl,
  - R<sup>19</sup> in each case independently of one another represent hydrogen or C<sub>1</sub>-C<sub>6</sub>-alkyl,
  - p independently of one another represents 0, 1, 2.

In the radical definitions mentioned as being preferred, halogen represents fluorine, chlorine, bromine and iodine, in particular fluorine, chlorine and bromine.

Particular preference is given to active compound combinations comprising compounds of the formula (I-1), in which

- R<sup>2</sup> represents hydrogen or methyl,
- represents C<sub>1</sub>-C<sub>4</sub>-alkyl (in particular methyl, ethyl, n-, isopropyl, n-, iso-, sec-, tert-butyl),
  - R<sup>4</sup> represents methyl, trifluoromethyl, trifluoromethoxy, fluorine, chlorine, bromine or iodine,
  - R<sup>5</sup> represents hydrogen, fluorine, chlorine, bromine, iodine, trifluoromethyl or trifluoromethoxy,

- R<sup>7</sup> represents chlorine or bromine,
- R<sup>9</sup> represents trifluoromethyl, chlorine, bromine, difluoromethoxy or trifluoroethoxy.

Very particular preference is given to active compound combinations comprising the following 5 compounds of the formula (I-1):

				·			
Example No.	R <sup>2</sup>	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>7</sup>	R <sup>9</sup>	m.p. (°C)
I-1-1 _	. Н	Me	Me	CI	Cl	CF <sub>3</sub>	185-186
I-1-2	H	Me	Me	Cl	Cl	OCH <sub>2</sub> CF <sub>3</sub>	207-208
I-1-3	H	Me	Me	Cl	Cl	Cl	225-226
I-1-4	H	Me	Me	Cl	Cl	Br	. 162-164
I-1-5	H	Me	Cl	Cl	. Cl	CF <sub>3</sub>	155-157
I-1-6	H	Me	Cl	Cl	Cl	OCH <sub>2</sub> CF <sub>3</sub>	192-195
I-1-7	Η	Me	Cl	Cl	Cl	Cl	205-206
I-1-8	H	Me	Cl	Cl	Cl	Br	245-246
I-1-9	Η	i-Pr	Me	Cl	Cl	CF <sub>3</sub>	195-196
I-1-10	$\mathbf{H}$	i-Pr	Me	Cl	Cl	OCH <sub>2</sub> CF <sub>3</sub>	217-218
I-1-11	H	i-Pr	Me	Cl	Cl	Cl	173-175
I-1-12.	Η	i-Pr	Me	Cl	CI ,	Br .	159-161
I-1-13	H	i-Pr	CI	Cl	CI	CF <sub>3</sub>	200-201
I-1-14	H	i-Pr	Cl	Cl	Cl	OCH <sub>2</sub> CF <sub>3</sub>	232-235
I-1-15	Η	i-Pr	Cl	Cl	Cl	Cl	. 197-199
I-1-16	H	· i-Pr	Cl	Cl	Cl	Br	188-190
I-1-17	H	Et	Me	Cl	Cl	CF <sub>3</sub>	163-164
I-1-18	Η	Et	Me	Cl	Cl	OCH <sub>2</sub> CF <sub>3</sub>	205-207
I-1-19	H	Et	Me	Cl	CI	Cl	199-200
I-1-20	H	Et	Me	Cl	CI	Br ·	194-195
I-1-21 .	H	· Et	CI	Cl	Cl-	CF <sub>3</sub>	201-202
I-1-22	H	Et	Cl	Cl	Cl	Cl	206-208
I-1-23	H	Et	Cl	Cl	Cl	Br	214-215
I-1-24	H	t-Bu	Me	Cl	Cl	CF <sub>3</sub>	223-225
I-1-25	H	· t-Bu	Me	Cl	Cl	Cl	163-165
I-1-26	H	t-Bu	Me	Cl	CI	Br	159-161
I-1-27	H	t-Bu	CI ·	CI	Cl	CF <sub>3</sub>	170-172
I-1-28 <sup>'</sup>	H	t-Bu	Cl	CI	Cl	Cl	172-173
I-1-29	Н	t-Bu	CI	Cl	Cl ·	Br	179-180
I-1-30	Н	Me	Me	Br	Ci	CF <sub>3</sub>	222-223
I-1-31	Н	Et	Me	Br	Cl	CF <sub>3</sub>	192-193
I-1-32	Н	i-Pr	Me	Br	CI	CF <sub>3</sub>	197-198

Example No.	R²	R <sup>3</sup>	R <sup>4</sup>	R <sup>5</sup>	R <sup>7</sup>	R <sup>9</sup>	m.p. (°C)
I-1-33	Н	t-Bu	Me	Br	Cl	CF <sub>3</sub>	247-248
I-1-34	Н	Me	Me	Br	Cl	Cl	140-141
I-1-35	Η̈́	Et	Me	Br	Cl	Cl	192-194
I-1-36	Н	i-Pr	Me	Br	Cl	Cl	152-153
I-1-37	H	t-Bu	Me	Br	Cl	Cl	224-225
I-1-38	Н	Me	Me	Br	Cl	Br	147-149
I-1-39	Н	Et	Me	Br	Cl	Br	194-196
I-1-40	Н	i-Pr	Me	Br	Cl	Br	185-187
I-1-41 .	Н	t-Bu	Me	Br	Cl	Br	215-221
I-1-42	Н	Me	Me	I	Cl	CF <sub>3</sub>	199-200
I-1-43	H	Et	Me	I.	Cl	CF <sub>3</sub>	199-200
I-1-44	Н	i-Pr	Me	I	Cl	CF <sub>3</sub>	188-189
I-1-45	Н	t-Bu	Me	I	Cl	CF <sub>3</sub>	242-243 ·
I-1-46	Н	Me	Me	I	Cl	C1	233-234
I-1-47 =	. Н	Et	Me	I	. Cl	Cl	196-197
I-1-48	H	i-Pr	Me	I	Cl	Cl	189-190
I-1-49	Н	t-Bu	Me	I	Cl	Cl	. 228-229
I-1-50	Н	Me	Me	I	· Cl	Br	. 229-230
I-1-51	H	iPr	Me	Ι.	CI	Br	191-192
I-1-52	Н	Me	Br	Br	Cl	CF <sub>3</sub>	162-163
I-1-53	Н	Et	Br	Br	Ċl	CF <sub>3</sub>	188-189
I-1-54	H	i-Pr	Br	Br	C1	$CF_3$	192-193
I-1-55	H	t-Bu	Br	Br	Cl	CF <sub>3</sub>	246-247
I-1-56	Н	Me	Br	Br	Cl	Cl	188-190
I-1-57	Н	Et	Br	Br	Cl	Cl	192-194
I-1-58	H	i-Pr	Br	Br	Cl	Cl	197-199
I-1-59	Η ΄	t-Bu	Br	Br	Cl	Cl	210-212
I-1-60	Н	Me	Br	Br	Cl	Br	166-168
I-1-61	Н	Et	Br	Br	Cl	Br	196-197
I-1-62	H	i-Pr	Br	Br	Cl	Br .	162-163
I-1-63 .	H	t-Bu	Br	Br	Cl	Br	194-196
I-1-64	H	t-Bu	Cl	Br	Cl	CF <sub>3</sub>	· 143-145
I-1-65	Me	Me	Br	Br'	Cl	Cl	153-155
I-1-66	Me	Me	Me	Br	Cl	CF <sub>3</sub>	207-208
I-1-67	Me	Me	· Cl	Cl	Cl	Cl.	231-232
I-1-68	Me	Me	Br ·	Br	Cl	Br	189-190
I-1-69	Me	Me	Cl	Cl	Cl	Br	216-218
I-1-70	Me	Me	Cl	Cl	CI	CF <sub>3</sub>	. 225-227
I-1-71	Me	Me	Br	Br	Cl	CF <sub>3</sub>	228-229
I-1-72	Н	i-Pr	Me	Н	Cl	CF <sub>3</sub>	237-239

Especially preferred are active compound combinations comprising a compound of the formulae below

5.

Pyrethroids are known active compounds having insecticidal and acaricidal properties. Preference is given to active compound combinations according to the invention which, preferably, comprise the following pyrethroids (active compounds of group 2):

# 10 (2-1) acrinathrin (known from EP-A 0 048 186)

and/or

5

(2-2) alpha-cypermethrin (known from EP-A 0 067 461)

# 15. and/or

(2-3) betacyfluthrin (known from EP-A 0 206 149)

and/or

(2-4) cyhalothrin (known from DE-A 28 02 962)

and/or

(2-5) cypermethrin (known from DE-A-2 326 077)

and/or

(2-6) deltamethrin (known from DE-A 23 26.077)

10

and/or

(2-7) esfenvalerate (known from DE-A 27 37 297)

and/or

15 (2-8) ethofenprox (known from DE-A 31 17 510)

and/or

(2-9) fenpropathrin (known from DE-A 22 31 312)

and/or

(2-10) fenvalerate (known from DE-A 23 35 347)

5 and/or

(2-11) flucythrinate (known from DE-A 27 57 066)

and/or

(2-12) lambda-cyhalothrin (known from EP-A 0 106 469)

10

and/or

(2-13) permethrin (known from DE-A 23 26 077)

and/or

15 (2-14) taufluvalinate (known from EP-A 0 038 617)

and/or ·

(2-15) tralomethrin (known from DE-A 27 42 546)

and/or

(2-16) zeta-cypermethrin (known from EP-A 0 026 542)

and/or

5 (2-17) cyfluthrin (known from DE-A 27 09 264)

and/or

or =

(2-18) bifenthrin (known from EP-A 0 049 977)

10 and/or

(2-19) cycloprothrin (known from DE-A 26 53 189)

and/or

(2-20) eflusilanate (known from DE-A 36 04 781)

and/or

15

(2-21) fubfenprox (known from DE-A 37 08 231)

and/or

(2-22) pyrethrin (known from The Pesticide Manual, 1997, 11th edition, p. 1056)

$$R^{20} = -CH_3 \text{ or } -CO_2CH_3$$

$$R^{21} = -CH = CH_2 \text{ or } -CH_3 \text{ or } -CH_2 CH_3$$

5 and/or

(2-23) resmethrin (known from GB-A 1 168 797)

and/or

na/or =

(2-24) gamma-cyhalothrin (known from GB-A 2 143 823)

10

Particularly preferably, the active compound combinations according to the invention comprise at least one pyrethroid of group 2 selected from

- (2-1) acrinathrin
- 15 (2-3) betacyfluthrin.
  - (2-5) cypermethrin.
  - (2-6) deltamethrin.
  - (2-12) lambda-cyhalothrin.
  - (2-14) taufluvalinate.
- 20 (2-24) gamma-cyhalothrin.

Especially preferred are active compound combinations comprising the compound of the formula (I-1-9) and a pyrethroid of group 2 selected from the compounds (2-1) to (2-24).

Especially preferred are active compound combinations comprising the compound of the formula (I-1-11) and a pyrethroid of group 2 selected from the compounds (2-1) to (2-24).

Especially preferred are active compound combinations comprising the compound of the formula (I-1-12) and a pyrethroid of group 2 selected from the compounds (2-1) to (2-24).

Emphasis is given to the following specifically mentioned active compound combinations (2-component mixtures) comprising a compound of the formula (I-1) and a pyrethroid of group 2:

No.	Active compound combination comprising	No.	Active compound combination comprising
la)	(I-1-1) and (2-1) acrinathrin	28a)	(I-1-39) and (2-1) acrinathrin
1b)	(I-1-1) and (2-1) betacyfluthrin	28b)	(I-1-39) and (2-3) betacyfluthrin
1c)	(I-1-1) and (2-5) cypermethrin	28c)	(I-1-39) and (2-3) betacy futili iii (I-1-39) and (2-5) cypermethrin
1d)	(I-1-1) and (2-6) deltamethrin	28d)	(I-1-39) and (2-6) deltamethrin
1e)	(I-1-1) and (2-12) lambda-cyhalothrin	28e)	(I-1-39) and (2-12) lambda-cyhalothrin
1f)	(I-1-1) and (2-12) fambua-cynaromini (I-1-1) and (2-14) taufluvalinate	28f)	(I-1-39) and (2-14) taufluvalinate
11) 1g)	(I-1-1) and (2-14) taunuvalinate (I-1-1) and (2-24) gamma-cyhalothrin	28g)	(I-1-39) and (2-14) tautiuvannate (I-1-39) and (2-24) gamma-cyhalothrin
2a)	(I-1-2) and (2-1) acrinathrin	20g) 29a)	(I-1-40) and (2-1) acrinathrin
2b)	(I-1-2) and (2-1) betacyfluthrin	29b)	(I-1-40) and (2-1) act matrix (I-1-40) and (2-3) betacyfluthrin
2c)	=(I-1-2) and (2-5) cypermethrin	29c)	(I-1-40) and (2-5) betacy flutiff in (I-1-40) and (2-5) cypermethrin
2d)	(I-1-2) and (2-6) deltamethrin	29d)	(I-1-40) and (2-5) deltamethrin
2e)	(I-1-2) and (2-12) lambda-cyhalothrin	29e)	(I-1-40) and (2-12) lambda-cyhalothrin
2f)	(I-1-2) and (2-14) taufluvalinate	29f)	(I-1-40) and (2-14) taufluvalinate
2g)	(I-1-2) and (2-24) gamma-cyhalothrin	29g)	(I-1-40) and (2-14) tauriavamate (I-1-40) and (2-24) gamma-cyhalothrin
3a)	(I-1-3) and (2-1) acrinathrin	30a)	(I-1-42) and (2-1) acrinathrin
3b)	(I-1-3) and (2-3) betacyfluthrin	30b)	(I-1-42) and (2-3) betacyfluthrin
· 3c)	(I-1-3) and (2-5) cypermethrin	30c)	(I-1-42) and (2-5) cypermethrin
3d)	(I-1-3) and (2-6) deltamethrin	30d)	(I-1-42) and (2-6) deltamethrin
3e)	(I-1-3) and (2-12) lambda-cyhalothrin	30e)	(I-1-42) and (2-12) lambda-cyhalothrin
3f)	(I-1-3) and (2-14) taufluvalinate	30f)	(I-1-42) and (2-14) taufluvalinate
3g)	(I-1-3) and (2-24) gamma-cyhalothrin	30g)	(I-1-42) and (2-24) gamma-cyhalothrin
4a)	(I-1-4) and (2-1) acrinathrin	31a)	(I-1-43) and (2-1) acrinathrin
4b)	(I-1-4) and (2-3) betacyfluthrin	31b)	(I-1-43) and (2-3) betacyfluthrin
4c)	(I-1-4) and (2-5) cypermethrin	31c)	(I-1-43) and (2-5) cypermethrin
4d)	(I-1-4) and (2-6) deltamethrin	31d)	(I-1-43) and (2-6) deltamethrin
4e) .	(I-1-4) and (2-12) lambda-cyhalothrin	31e)	(I-1-43) and (2-12) lambda-cyhalothrin
4f)	(I-1-4) and (2-14) taufluvalinate	31f)	(I-1-43) and (2-14) taufluvalinate
4g)	(I-1-4) and (2-24) gamma-cyhalothrin	31g)	(I-1-43) and (2-24) gamma-cyhalothrin
5a)	(I-1-5) and (2-1) acrinathrin	32a)	(I-1-44) and (2-1) acrinathrin
5b)	(I-1-5) and (2-3) betacyfluthrin	32b)	(I-1-44) and (2-3) betacyfluthrin
5c)	(I-1-5) and (2-5) cypermethrin	32c)	(I-1-44) and (2-5) cypermethrin
5d)	(I-1-5) and (2-6) deltamethrin	32d)	(I-1-44) and (2-6) deltamethrin
5e) ·	(I-1-5) and (2-12) lambda-cyhalothrin	32e)	(I-1-44) and (2-12) lambda-cyhalothrin
5f)	(I-1-5) and (2-14) taufluvalinate	32f)	(I-1-44) and (2-14) taufluvalinate
5g)	(I-1-5) and (2-24) gamma-cyhalothrin	32g)	(I-1-44) and (2-24) gamma-cyhalothrin
6a)	(I-1-6) and (2-1) acrinathrin	33a)	(I-1-50) and (2-1) acrinathrin

NI.	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		I
No.	Active compound combination comprising	No.	Active compound combination comprising
6b)	(I-1-6) and (2-3) betacyfluthrin	33b)	(I-1-50) and (2-3) betacyfluthrin
6c)	(I-1-6) and (2-5) cypermethrin	33c)	(I-1-50) and (2-5) cypermethrin
6d)	(I-1-6) and (2-6) deltamethrin	33d)	(I-1-50) and (2-6) deltamethrin
6e)	(I-1-6) and (2-12) lambda-cyhalothrin	33e)	(I-1-50) and (2-12) lambda-cyhalothrin
6f)	(I-1-6) and (2-14) taufluvalinate	33f)	(I-1-50) and (2-14) taufluvalinate
6g)	(I-1-6) and (2-24) gamma-cyhalothrin	33g)	(I-1-50) and (2-24) gamma-cyhalothrin
7a)	(I-1-7) and (2-1) acrinathrin	34a)	(I-1-51) and (2-1) acrinathrin
7b)	(I-1-7) and (2-3) betacyfluthrin	34b)	(I-1-51) and (2-3) betacyfluthrin
7c)	(I-1-7) and (2-5) cypermethrin	34c)	(I-1-51) and (2-5) cypermethrin
7d)	(I-1-7) and (2-6) deltamethrin	34d)	(I-1-51) and (2-6) deltamethrin
7e)	(I-1-7) and (2-12) lambda-cyhalothrin	· 34e)	(I-1-51) and (2-12) lambda-cyhalothrin
7f) ·	(I-1-7) and (2-14) taufluvalinate	34f)	(I-1-51) and (2-14) taufluvalinate
.7g)	(I-1-7) and (2-24) gamma-cyhalothrin	34g)	(I-1-51) and (2-24) gamma-cyhalothrin
8a)	(I-1-8) and (2-1) acrinathrin	35a)	(I-1-52) and (2-1) acrinathrin
8b)	(I-1-8) and (2-3) betacyfluthrin	35b)	(I-1-52) and (2-3) betacyfluthrin
8c)	(I-1-8) and (2-5) cypermethrin	35c)	(I-1-52) and (2-5) cypermethrin
8d)	(I-1-8) and (2-6) deltamethrin	35d)	(I-1-52) and (2-6) deltamethrin
8e)	(I-1-8) and (2-12) lambda-cyhalothrin	35e)	(I-1-52) and (2-12) lambda-cyhalothrin
8f)	(I-1-8) and (2-14) taufluvalinate	35f)	(I-1-52) and (2-14) taufluvalinate
8g)	(I-1-8) and (2-24) gamma-cyhalothrin	35g)	(I-1-52) and (2-24) gamma-cyhalothrin
9a)	(I-1-9) and (2-1) acrinathrin	36a)	(I-1-53) and (2-1) acrinathrin
9b)	(I-1-9) and (2-3) betacyfluthrin	36b)	(I-1-53) and (2-3) betacyfluthrin
9c)	(I-1-9) and (2-5) cypermethrin	36c)	(I-1-53) and (2-5) cypermethrin
9d)	(I-1-9) and (2-6) deltamethrin	36d)	(I-1-53) and (2-6) deltamethrin
9e)	(I-1-9) and (2-12) lambda-cyhalothrin	36e)	(I-1-53) and (2-12) lambda-cyhalothrin
9f)	(I-1-9) and (2-14) taufluvalinate	36f)	(I-1-53) and (2-14) taufluvalinate
9g)	(I-1-9) and (2-24) gamma-cyhalothrin	36g)	(I-1-53) and (2-24) gamma-cyhalothrin
10a)	(I-1-11) and (2-1) acrinathrin	37a)	(I-1-54) and (2-1) acrinathrin
10b)	(I-1-11) and (2-3) betacyfluthrin	37b)	(I-1-54) and (2-3) betacyfluthrin
10c)	(I-1-11) and (2-5) cypermethrin	37c)	(I-1-54) and (2-5) cypermethrin
10d)	(I-1-11) and (2-6) deltamethrin	37d)	(I-1-54) and (2-6) deltamethrin
10e)	(I-1-11) and (2-12) lambda-cyhalothrin	37e)	(I-1-54) and (2-12) lambda-cyhalothrin
10f)	(I-1-11) and (2-14) taufluvalinate	37f)	(I-1-54) and (2-14) taufluvalinate
10g)	(I-1-11) and (2-24) gamma-cyhalothrin	37g)	(I-1-54) and (2-24) gamma-cyhalothrin
lla)	(I-1-12) and (2-1) acrinathrin	38a)	(I-1-55) and (2-1) acrinathrin
11b)	(I-1-12) and (2-3) betacyfluthrin	38ь)	(I-1-55) and (2-3) betacyfluthrin
llc)	(I-1-12) and (2-5) cypermethrin	38c)	(I-1-55) and (2-5) cypermethrin
11d)	(I-1-12) and (2-6) deltamethrin	38d)	(I-1-55) and (2-6) deltamethrin
11e)	(I-1-12) and (2-12) lambda-cyhalothrin	38e)	(I-1-55) and (2-12) lambda-cyhalothrin
11f)	(I-1-12) and (2-14) taufluvalinate	38f)	(I-1-55) and (2-14) taufluvalinate

NI-	A	N-	I A saline a series of a serie
No.	Active compound combination comprising	No.	Active compound combination comprising
11g)	(I-1-12) and (2-24) gamma-cyhalothrin	38g)	(I-1-55) and (2-24) gamma-cyhalothrin
12a)	(I-1-13) and (2-1) acrinathrin	39a)	(I-1-56) and (2-1) acrinathrin
12b)	(I-1-13) and (2-3) betacyfluthrin	39b)	(I-1-56) and (2-3) betacyfluthrin
12c)	(I-1-13) and (2-5) cypermethrin	39c)	(I-1-56) and (2-5) cypermethrin
12d)	(I-1-13) and (2-6) deltamethrin	39d)	(I-1-56) and (2-6) deltamethrin
12e)	(I-1-13) and (2-12) lambda-cyhalothrin	39e)	(I-1-56) and (2-12) lambda-cyhalothrin
12f)	(I-1-13) and (2-14) taufluvalinate	39f)	(I-1-56) and (2-14) taufluvalinate
12g)	(I-1-13) and (2-24) gamma-cyhalothrin	39g)	(I-1-56) and (2-24) gamma-cyhalothrin
13a)	(I-1-15) and (2-1) acrinathrin	40a)	(I-1-57) and (2-1) acrinathrin
13b)	(I-1-15) and (2-3) betacyfluthrin	40b)	(I-1-57) and (2-3) betacyfluthrin
13c)	(I-1-15) and (2-5) cypermethrin	`40c)	(I-1-57) and (2-5) cypermethrin
13 <b>d</b> )	(I-1-15) and (2-6) deltamethrin	40d)	(I-1-57) and (2-6) deltamethrin
13e)	(I-£15) and (2-12) lambda-cyhalothrin	40e)	(I-1-57) and (2-12) lambda-cyhalothrin
13f)	(F-1-15) and (2-14) taufluvalinate	40f)	(I-1-57) and (2-14) taufluvalinate
13g)	(I-1-15) and (2-24) gamma-cyhalothrin	40g)	(I-1-57) and (2-24) gamma-cyhalothrin
· 14a)	(I-1-16) and (2-1) acrinathrin	41a)	(I-1-58) and (2-1) acrinathrin
14b)	(I-1-16) and (2-3) betacyfluthrin	41b)	(I-1-58) and (2-3) betacyfluthrin
14c)	(I-1-16) and (2-5) cypermethrin	41c)	(I-1-58) and (2-5) cypermethrin
14d)	(I-1-16) and (2-6) deltamethrin	41d)	(I-1-58) and (2-6) deltamethrin
14e)	(I-1-16) and (2-12) lambda-cyhalothrin	41e)	(I-1-58) and (2-12) lambda-cyhalothrin
· 14f)	(I-1-16) and (2-14) taufluvalinate	41f)	(I-1-58) and (2-14) taufluvalinate
14g)	(I-1-16) and (2-24) gamma-cyhalothrin	41g)	(I-1-58) and (2-24) gamma-cyhalothrin
15a)	(I-1-19) and (2-1) acrinathrin	42a)	(I-1-60) and (2-1) acrinathrin
15b)	(I-1-19) and (2-3) betacyfluthrin	42b)	(I-1-60) and (2-3) betacyfluthrin
15c)	(I-1-19) and (2-5) cypermethrin	42c)	(I-1-60) and (2-5) cypermethrin
. 15d)	(I-1-19) and (2-6) deltamethrin	42d)	(I-1-60) and (2-6) deltamethrin
15e)	(I-1-19) and (2-12) lambda-cyhalothrin	42e)	(I-1-60) and (2-12) lambda-cyhalothrin
15f)	(I-1-19) and (2-14) taufluvalinate	42f)	(I-1-60) and (2-14) taufluvalinate
15g)	(I-1-19) and (2-24) gamma-cyhalothrin	42g)	(I-1-60) and (2-24) gamma-cyhalothrin
16a)	(I-1-21) and (2-1) acrinathrin	43a)	(I-1-61) and (2-1) acrinathrin
16b)	(I-1-21) and (2-3) betacyfluthrin	43b)	(I-1-61) and (2-3) betacyfluthrin
16c)	(I-1-21) and (2-5) cypermethrin	43c)	(I-1-61) and (2-5) cypermethrin
16d)	(I-1-21) and (2-6) deltamethrin	43d)	(I-1-61) and (2-6) deltamethrin
16e)	(I-1-21) and (2-12) lambda-cyhalothrin	43e)	(I-1-61) and (2-12) lambda-cyhalothrin
16f)	(I-1-21) and (2-14) taufluvalinate	43f)	(I-1-61) and (2-14) taufluvalinate
16g)	(I-1-21) and (2-24) gamma-cyhalothrin	43g)	(I-1-61) and (2-24) gamma-cyhalothrin
17a)	(I-1-22) and (2-1) acrinathrin	44a)	(I-1-62) and (2-1) acrinathrin
17b)	(I-1-22) and (2-3) betacyfluthrin	44b)	(I-1-62) and (2-3) betacyfluthrin
17c)	(I-1-22) and (2-5) cypermethrin	44c)	(I-1-62) and (2-5) cypermethrin
17d)	(I-1-22) and (2-6) deltamethrin	44d)	(I-1-62) and (2-6) deltamethrin

17e  (I-1-22) and (2-12) lambda-cyhalothrin (1-1-62) and (2-14) taufluvalinate (17f) (I-1-22) and (2-24) gamma-cyhalothrin (I-1-62) and (2-24) gamma-cyhalothrin (I-1-63) and (2-3) betacyfluthrin (I-1-64) and (2-1) acrinathrin (I-1-64) and (2-3) betacyfluthrin (I-1-64) and (2-14) taufluvalinate (I-1-23) and (2-12) lambda-cyhalothrin (I-1-64) and (2-14) taufluvalinate (I-1-23) and (2-14) taufluvalinate (I-1-65) and (2-14) taufluvalinate (I-1-66) and (2-3) betacyfluthrin (I-1-67) and (2-13) taufluvalinate (I-1-67) and (2-24) taufluvalinate (I-1-67) and (2-24) taufluvalinate (I-1-68) and (2-24				
(I-1-22) and (2-14) taufluvalinate	No.	Active compound combination comprising	No.	Active compound combination comprising
(1-1-22) and (2-24) gamma-cyhalothrin (1-1-23) and (2-1) acrinathrin (1-1-24) and (2-3) betacyfluthrin (1-1-24) and (2-1) lambda-cyhalothrin (1-1-24) and (2-12) lambda-cyhalothrin (1-1-24) and (2-13) betacyfluthrin (1-1-24) and (2-14) taufluvalinate (1-1-25) and (2-14) taufluvalinate (1-1-26) and (2-12) lambda-cyhalothrin (1-1-26) and (2-13) betacyfluthrin (1-1-26) and (2-13) betacyfluthrin (1-1-26) and (2-14) taufluvalinate (1-1-26) and (2-13) betacyfluthrin (1-1-26) and (2-14) taufluvalinate (1-1-27) and (2-13) betacyfluthrin (1-1-26) and (2-14) taufluvalinate (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-14) taufluvalinate (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-14) taufluvalinate (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-13) betacyfluthrin (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-13) taufluvalinate (1-1-29)	17e)	(I-1-22) and (2-12) lambda-cyhalothrin	44e)	(I-1-62) and (2-12) lambda-cyhalothrin
18a)	17f)	(I-1-22) and (2-14) taufluvalinate	44f)	(I-1-62) and (2-14) taufluvalinate
18b   (I-1-23) and (2-3) betacyfluthrin   45b   (I-1-64) and (2-3) betacyfluthrin   45c   (I-1-64) and (2-5) cypermethrin   45d   (I-1-23) and (2-12) lambda-cyhalothrin   45e   (I-1-23) and (2-12) lambda-cyhalothrin   45e   (I-1-23) and (2-14) taufluvalinate   45f   (I-1-23) and (2-14) taufluvalinate   45g   (I-1-23) and (2-24) gamma-cyhalothrin   46a   (I-1-24) and (2-3) betacyfluthrin   46b   (I-1-24) and (2-3) betacyfluthrin   46c   (I-1-65) and (2-1) acrinathrin   46e   (I-1-24) and (2-12) lambda-cyhalothrin   46e   (I-1-24) and (2-12) lambda-cyhalothrin   46e   (I-1-24) and (2-12) lambda-cyhalothrin   46g   (I-1-24) and (2-12) lambda-cyhalothrin   46g   (I-1-24) and (2-12) lambda-cyhalothrin   47e   (I-1-66) and (2-13) betacyfluthrin   47e   (I-1-26) and (2-13) betacyfluthrin   47e   (I-1-26) and (2-14) taufluvalinate   47e   (I-1-26) and (2-14) taufluvalinate   47e   (I-1-26) and (2-14) taufluvalinate   47e   (I-1-27) and (2-3) betacyfluthrin   47e   (I-1-26) and (2-14) taufluvalinate   47e   (I-1-27) and (2-3) betacyfluthrin   47e   (I-1-27) and (2-1) acrinathrin   48e   (I-1-27) and (2-1) acrinathrin   48e   (I-1-27) and (2-14) taufluvalinate   48f   (I-1-29) and (2-13) betacyfluthrin   49e   (I-1-29) and (2-13) betacyfluthrin   49e   (I-1-29) and (2-13) lambda-cyhalothrin   49e   (I-1-29) and (2-13) lambda-cyhalothrin   49e   (I-1-29) and (2-13) lambda-cyhalothrin   49e   (I-1-29) and (2-14) taufluvalinate   49f   (I-1-29) and (2-14) taufluvalinate   4	17g)	(I-1-22) and (2-24) gamma-cyhalothrin	44g)	(I-1-62) and (2-24) gamma-cyhalothrin
18c  (I-1-23) and (2-5) cypermethrin (I-1-23) and (2-10) lambda-cyhalothrin (I-1-23) and (2-12) lambda-cyhalothrin (I-1-23) and (2-12) lambda-cyhalothrin (I-1-23) and (2-14) taufluvalinate (I-1-24) and (2-12) acrinathrin (I-1-24) and (2-13) betacyfluthrin (I-1-24) and (2-3) betacyfluthrin (I-1-24) and (2-3) betacyfluthrin (I-1-24) and (2-12) lambda-cyhalothrin (I-1-24) and (2-3) betacyfluthrin (I-1-24) and (2-12) lambda-cyhalothrin (I-1-24) and (2-12) lambda-cyhalothrin (I-1-24) and (2-12) lambda-cyhalothrin (I-1-24) and (2-12) lambda-cyhalothrin (I-1-25) and (2-12) lambda-cyhalothrin (I-1-26) and (2-13) betacyfluthrin (I-1-26) and (2-13) betacyfluthrin (I-1-26) and (2-13) betacyfluthrin (I-1-26) and (2-13) betacyfluthrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-12) lambda-cyhalothrin (I-1-26) and (2-12) lambda-cyhalothrin (I-1-26) and (2-12) lambda-cyhalothrin (I-1-26) and (2-12) lambda-cyhalothrin (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-13) carinathrin (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-13) betacyfluthrin (I-1-28) and (2-13) cypermethrin (I-1-28) and (2-13) betacyfluthrin (I-1-28) a	18a)	(I-1-23) and (2-1) acrinathrin	45a)	(I-1-64) and (2-1) acrinathrin
18d)	18b)	(I-1-23) and (2-3) betacyfluthrin	45b)	(I-1-64) and (2-3) betacyfluthrin
18e)	18c)	(I-1-23) and (2-5) cypermethrin	45c)	(I-1-64) and (2-5) cypermethrin
18f)	18d)	(I-1-23) and (2-6) deltamethrin	45d)	(I-1-64) and (2-6) deltamethrin
18g)   (I-1-23) and (2-24) gamma-cyhalothrin   19a)   (I-1-24) and (2-1) acrinathrin   46a)   (I-1-65) and (2-1) acrinathrin   46b)   (I-1-24) and (2-3) betacyfluthrin   46c)   (I-1-65) and (2-3) betacyfluthrin   46d)   (I-1-65) and (2-3) betacyfluthrin   46d)   (I-1-24) and (2-12) lambda-cyhalothrin   46d)   (I-1-26) and (2-12) lambda-cyhalothrin   47d)   (I-1-26) and (2-12) acrinathrin   47d)   (I-1-26) and (2-23) betacyfluthrin   47d)   (I-1-26) and (2-12) lambda-cyhalothrin   47d)   (I-1-26) and (2-13) betacyfluthrin   47d)   (I-1-26) and (2-14) taufluvalinate   47f)   (I-1-27) and (2-3) betacyfluthrin   48b)   (I-1-66) and (2-14) taufluvalinate   48d)   (I-1-67) and (2-13) betacyfluthrin   48d)   (I-1-67) and (2-13) betacyfluthrin   48d)   (I-1-67) and (2-14) taufluvalinate   48f)   (I-1-27) and (2-14) taufluvalinate   48f)   (I-1-27) and (2-14) taufluvalinate   48f)   (I-1-27) and (2-12) lambda-cyhalothrin   48d)   (I-1-67) and (2-12) lambda-cyhalothrin   47d)   (I-1-27) and (2-13) betacyfluthrin   48d)   (I-1-67) and (2-13) betacyfluthrin   48d)   (I-1-67) and (2-14) taufluvalinate   48f)   (I-1-68) and (2-13) betacyfluthrin   49d)   (I-1-68) and (2-13) betacyfluthrin   49d)   (I-1-68) and (2-14) taufluvalinate   49d)   (I-1-68) and (2-14) taufluval	18e)	(I-1-23) and (2-12) lambda-cyhalothrin	45e)	(I-1-64) and (2-12) lambda-cyhalothrin
19a	18f)	(I-1-23) and (2-14) taufluvalinate	45f)	(I-1-64) and (2-14) taufluvalinate
19b	18g)	(I-1-23) and (2-24) gamma-cyhalothrin	45g)	(I-1-64) and (2-24) gamma-cyhalothrin
19c   (I-1-24) and (2-5) cypermethrin   46c    (I-1-65) and (2-5) cypermethrin   46d    (I-1-65) and (2-6) deltamethrin   46d    (I-1-65) and (2-6) deltamethrin   46e    (I-1-65) and (2-12) lambda-cyhalothrin   46e    (I-1-65) and (2-12) lambda-cyhalothrin   46e    (I-1-24) and (2-14) taufluvalinate   46f    (I-1-65) and (2-12) lambda-cyhalothrin   47a    (I-1-66) and (2-13) betacyfluthrin   47b    (I-1-66) and (2-3) betacyfluthrin   47c    (I-1-66) and (2-3) betacyfluthrin   47c    (I-1-26) and (2-13) lambda-cyhalothrin   47c    (I-1-26) and (2-13) lambda-cyhalothrin   47c    (I-1-26) and (2-12) lambda-cyhalothrin   47c    (I-1-26) and (2-13) lambda-cyhalothrin   47c    (I-1-26) and (2-14) taufluvalinate   47f    (I-1-26) and (2-12) lambda-cyhalothrin   47c    (I-1-26) and (2-14) taufluvalinate   47f    (I-1-66) and (2-12) lambda-cyhalothrin   47c    (I-1-26) and (2-14) taufluvalinate   47f    (I-1-66) and (2-12) lambda-cyhalothrin   47c    (I-1-27) and (2-13) betacyfluthrin   47c    (I-1-66) and (2-13) lambda-cyhalothrin   47c    (I-1-66) and (2-14) taufluvalinate   47f    (I-1-66) and (2-12) lambda-cyhalothrin   47c    (I-1-66) and (2-14) taufluvalinate   47f    (I-1-66) and (2-12) lambda-cyhalothrin   47c    (I-1-67) and (2-13) betacyfluthrin   47c    (I-1-66) and (2-14) taufluvalinate   47f    (I-1-66) and (2-14) taufluvalinate   47f    (I-1-67) and (2-13) betacyfluthrin   47c    (I-1-67) and (2-14) taufluvalinate   47f    (I-1-67) and (2-13) betacyfluthrin   47c    (I-1-67) and (2-13) betacyfluthrin   47c    (I-1-67) and (2-14) taufluvalinate   47f    (I-1-67) and (2-13) betacyfluthrin   47c    (I-1-67) and (2-14) taufluvalinate   47c    (I-1-67) and (2-12) lambda-cyhalothrin   47c    (I-1-68) and (2-13) betacyfluthrin   47c    (I-1-68) and (2-13) betacyfluthrin   47c    (I-1-68) and	19a)	(I-1-24) and (2-1) acrinathrin	46a)	(I-1-65) and (2-1) acrinathrin
19d)   (1-1-24) and (2-6) deltamethrin   19e)   (1-1-24) and (2-12) lambda-cyhalothrin   19f)   (1-1-24) and (2-14) taufluvalinate   19g)   (1-1-24) and (2-24) gamma-cyhalothrin   20a)   (1-1-26) and (2-1) acrinathrin   47a)   (1-1-66) and (2-1) acrinathrin   47b)   (1-1-66) and (2-3) betacyfluthrin   47c)   (1-1-66) and (2-3) betacyfluthrin   47d)   (1-1-66) and (2-3) betacyfluthrin   47e)   (1-1-66) and (2-3) betacyfluthrin   47e)   (1-1-66) and (2-3) betacyfluthrin   47e)   (1-1-66) and (2-6) deltamethrin   47e)   (1-1-66) and (2-12) lambda-cyhalothrin   47e)   (1-1-66) and (2-14) taufluvalinate   47f)   (1-1-66) and (2-14) taufluvalinate   47f)   (1-1-67) and (2-14) taufluvalinate   47f)   (1-1-67) and (2-14) taufluvalinate   48h   (1-1-67) and (2-13) betacyfluthrin   48h   (1-1-67) and (2-13) betacyfluthrin   48h   (1-1-67) and (2-14) taufluvalinate   48f   (1-1-67) and (2-14) taufluvalinate   48f   (1-1-68) and (2-14) taufluvalinate   47f   (1-1-68) and (2-14) taufluvalinate   48f   (1-1-67) and (2-14) taufluvalinate   48f   (1-1-68) and (2-14) taufluvalinate   47f   (1-1-68) and (2-14) taufluvalinate   48f   (1-1-67) and (2-14) taufluvalinate   48f   (1-1-68) and (2-14) taufluvalinate   49h   (1-1-68) and (2-13) betacyfluthrin   49c   (1-1-68) and (2-14) taufluvalinate   49f   (1-1-68) and (2-14) taufluvalinate   49f   (1-1-68) and (2-14) taufluvalinate   49f   (1-1-68) and (2-24) gamma-cyhalothrin   49g   (1-1-68) and (2-14) taufluvalinate   49f   (1-1-68) and (2-24) gamma-cyhalothrin   49g   (1-1-6	19b)	(I-1-24) and (2-3) betacyfluthrin	46b)	(I-1-65) and (2-3) betacyfluthrin
19e)   (I-1-24) and (2-12) lambda-cyhalothrin   19f)   (I-1-24) and (2-14) taufluvalinate   46f)   (I-1-65) and (2-14) taufluvalinate   19g)   (I-1-24) and (2-24) gamma-cyhalothrin   46g)   (I-1-26) and (2-13) betacyfluthrin   47a)   (I-1-66) and (2-14) taufluvalinate   47b)   (I-1-26) and (2-3) betacyfluthrin   47c)   (I-1-66) and (2-3) betacyfluthrin   47c)   (I-1-66) and (2-3) betacyfluthrin   47c)   (I-1-26) and (2-6) deltamethrin   47d)   (I-1-66) and (2-5) cypermethrin   47e)   (I-1-26) and (2-12) lambda-cyhalothrin   47e)   (I-1-26) and (2-14) taufluvalinate   47f)   (I-1-66) and (2-12) lambda-cyhalothrin   47g)   (I-1-26) and (2-14) taufluvalinate   47g)   (I-1-26) and (2-14) taufluvalinate   47g)   (I-1-26) and (2-14) gamma-cyhalothrin   48a)   (I-1-27) and (2-3) betacyfluthrin   48b)   (I-1-27) and (2-3) betacyfluthrin   48c)   (I-1-27) and (2-12) lambda-cyhalothrin   48f)   (I-1-27) and (2-12) lambda-cyhalothrin   48g)   (I-1-27) and (2-14) taufluvalinate   48f)   (I-1-29) and (2-14) taufluvalinate   48g)   (I-1-29) and (2-13) betacyfluthrin   49a)   (I-1-29) and (2-12) lambda-cyhalothrin   49c)   (I-1-29) and (2-12) lambda-cyhalothrin   49c)   (I-1-29) and (2-12) lambda-cyhalothrin   49c)   (I-1-29) and (2-14) taufluvalinate   49f)   (I-1-68) and (2-14) taufluvali	19c)	<u>_(</u> I-1-24) and (2-5) cypermethrin	46c)	(I-1-65) and (2-5) cypermethrin
19f)	19d)	(I-1-24) and (2-6) deltamethrin	46d)	(I-1-65) and (2-6) deltamethrin
(I-1-24) and (2-24) gamma-cyhalothrin (I-1-26) and (2-1) acrinathrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-3) betacyfluthrin (I-1-26) and (2-5) cypermethrin (I-1-26) and (2-5) cypermethrin (I-1-26) and (2-1) lambda-cyhalothrin (I-1-26) and (2-12) lambda-cyhalothrin (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-13) betacyfluthrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-14) taufluvalinate (I-1-67) and (2-3) betacyfluthrin (I-1-67) and (2-3) betacyfluthrin (I-1-67) and (2-6) deltamethrin (I-1-67) and (2-12) lambda-cyhalothrin (I-1-29) and (2-14) taufluvalinate (I-1-68) and (2-14) taufluvalinate (I-1-68) and (2-14) taufluvalinate (I-1-68) and (2-13) betacyfluthrin (I-1-68) and (2-12) lambda-cyhalothrin (I-1-29) and (2-12) lambda-cyhalothrin (I-1-68) and (2-12) lambda-cyhalothrin (I-1-29) and (2-14) taufluvalinate (I-1-68) and (2-12) lambda-cyhalothrin (I-1-68) and (2-12) lambda-cyhalothrin (I-1-68) and (2-14) taufluvalinate (I-1-68) and (2-14)	19e)	(I-1-24) and (2-12) lambda-cyhalothrin	46e)	(I-1-65) and (2-12) lambda-cyhalothrin
20a)         (I-1-26) and (2-1) acrinathrin         47a)         (I-1-66) and (2-1) acrinathrin           20b)         (I-1-26) and (2-3) betacyfluthrin         47b)         (I-1-66) and (2-3) betacyfluthrin           20c)         (I-1-26) and (2-5) cypermethrin         47c)         (I-1-66) and (2-5) cypermethrin           20d)         (I-1-26) and (2-6) deltamethrin         47d)         (I-1-66) and (2-5) cypermethrin           20e)         (I-1-26) and (2-12) lambda-cyhalothrin         47e)         (I-1-66) and (2-12) lambda-cyhalothrin           20f)         (I-1-26) and (2-14) taufluvalinate         47f)         (I-1-66) and (2-12) lambda-cyhalothrin           20g)         (I-1-26) and (2-24) gamma-cyhalothrin         47g)         (I-1-66) and (2-14) taufluvalinate           20g)         (I-1-27) and (2-14) taurluvalinate         48a)         (I-1-66) and (2-14) gamma-cyhalothrin           21a)         (I-1-27) and (2-1) acrinathrin         48a)         (I-1-67) and (2-1) acrinathrin           21b)         (I-1-27) and (2-5) cypermethrin         48c)         (I-1-67) and (2-5) cypermethrin           21c)         (I-1-27) and (2-6) deltamethrin         48d)         (I-1-67) and (2-6) deltamethrin           21e)         (I-1-27) and (2-14) taufluvalinate         48f)         (I-1-67) and (2-14) taufluvalinate           21g)         (I-1-29) and (2-24) g	19f)	(I-1-24) and (2-14) taufluvalinate	46f)	(I-1-65) and (2-14) taufluvalinate
(1-1-26) and (2-3) betacyfluthrin (1-1-26) and (2-5) cypermethrin (1-1-26) and (2-6) deltamethrin (1-1-26) and (2-12) lambda-cyhalothrin (1-1-26) and (2-12) lambda-cyhalothrin (1-1-26) and (2-14) taufluvalinate (1-1-27) and (2-14) acrinathrin (1-1-27) and (2-12) lambda-cyhalothrin (1-1-27) and (2-13) betacyfluthrin (1-1-27) and (2-14) taufluvalinate (1-1-27) and (2-15) cypermethrin (1-1-27) and (2-16) deltamethrin (1-1-27) and (2-19) lambda-cyhalothrin (1-1-27) and (2-14) taufluvalinate (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-14) taufluvalinate (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-14) taufluvalinate (1-1-29) and (2-13) betacyfluthrin (1-1-29) and (2-14) taufluvalinate (1-1-29) and (2-15) cypermethrin (1-1-29) and (2-15) cypermethrin (1-1-29) and (2-15) cypermethrin (1-1-29) and (2-15) cypermethrin (1-1-29) and (2-16) deltamethrin (1-1-28) and (2-16) deltamethrin and (2-16) deltamethrin (1-1	19g)	(I-1-24) and (2-24) gamma-cyhalothrin	46g)	(I-1-65) and (2-24) gamma-cyhalothrin
20c)	20a)	(I-1-26) and (2-1) acrinathrin	47a)	(I-1-66) and (2-1) acrinathrin
(I-1-26) and (2-6) deltamethrin   47d   (I-1-66) and (2-6) deltamethrin   47e   (I-1-26) and (2-12) lambda-cyhalothrin   47e   (I-1-26) and (2-12) lambda-cyhalothrin   47e   (I-1-66) and (2-12) lambda-cyhalothrin   47e   (I-1-66) and (2-14) taufluvalinate   47f   (I-1-66) and (2-14) taufluvalinate   47g   (I-1-26) and (2-24) gamma-cyhalothrin   47g   (I-1-27) and (2-1) acrinathrin   48a   (I-1-67) and (2-1) acrinathrin   48b   (I-1-67) and (2-1) acrinathrin   48b   (I-1-67) and (2-3) betacyfluthrin   48c   (I-1-67) and (2-5) cypermethrin   48d   (I-1-67) and (2-6) deltamethrin   48d   (I-1-67) and (2-6) deltamethrin   48f   (I-1-27) and (2-12) lambda-cyhalothrin   48f   (I-1-67) and (2-12) lambda-cyhalothrin   48g   (I-1-27) and (2-24) gamma-cyhalothrin   49a   (I-1-68) and (2-1) acrinathrin   49b   (I-1-68) and (2-5) cypermethrin   49c   (I-1-29) and (2-12) lambda-cyhalothrin   49d   (I-1-68) and (2-14) taufluvalinate   49f   (I-1-68) and (2-24) gamma-cyhalothrin   49d   (I-1-68) and (2-14) taufluvalinate   49f   (I-1-68) and (2-24) gamma-cyhalothrin   49g   (I-1-68) and (2-24) gamma-cyhalothrin   49d   (I-1-68) and (2-14) taufluvalinate   49f   (I-1-68) and (2-24) gamma-cyhalothrin   49d   (I-1-68) and (2-24) gamma-cyhalothrin   49d	20ь)	(I-1-26) and (2-3) betacyfluthrin	47b)	(I-1-66) and (2-3) betacyfluthrin
(I-1-26) and (2-12) lambda-cyhalothrin (I-1-26) and (2-14) taufluvalinate (I-1-26) and (2-14) taufluvalinate (I-1-26) and (2-24) gamma-cyhalothrin (I-1-26) and (2-24) gamma-cyhalothrin (I-1-27) and (2-1) acrinathrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-3) betacyfluthrin (I-1-27) and (2-5) cypermethrin (I-1-27) and (2-6) deltamethrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-12) lambda-cyhalothrin (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-14) taufluvalinate (I-1-27) and (2-14) taufluvalinate (I-1-29) and (2-13) betacyfluthrin (I-1-29) and (2-13) betacyfluthrin (I-1-29) and (2-14) taufluvalinate (I-1-29) and (2-15) cypermethrin (I-1-29) and (2-16) deltamethrin (I-1-28) and (2-16) deltamethrin (I-1-28) and (2-17) acrinathrin (I-1-28) and (2-18) and (2-19) and (2-19) and (2-19) lambda-cyhalothrin (I-1-29) and (2-14) taufluvalinate (I-1-28) and (2-12) lambda-cyhalothrin (I-1-29) and (2-14) taufluvalinate (I-1-28) and (2-14) taufluvalinate (I-1-29) and (2-14) taufluvalinate (I-1-29) and (2-24) gamma-cyhalothrin (I-1-28) and (2-24) gamma-cyhalothrin (I-1-29) and (2-24) gamma-cyhalothrin (I-1-29) and (2-24) gamma-cyhalothrin (I-1-29) and (2-24) gamma-cyhalothrin (I-1-28) and (2-24) gamma-cyhalothrin (I-1-29) and (2-24) gamma-cyhalothrin (I-1-28) and (2-24) gamma-cyhalothrin (I-1-29) and (2-24) gamma-cyhalothrin	20c)	(I-1-26) and (2-5) cypermethrin	47c)	(I-1-66) and (2-5) cypermethrin
20f)         (I-1-26) and (2-14) taufluvalinate         47f)         (I-1-66) and (2-14) taufluvalinate           20g)         (I-1-26) and (2-24) gamma-cyhalothrin         47g)         (I-1-66) and (2-24) gamma-cyhalothrin           21a)         (I-1-27) and (2-1) acrinathrin         48a)         (I-1-67) and (2-1) acrinathrin           21b)         (I-1-27) and (2-3) betacyfluthrin         48b)         (I-1-67) and (2-3) betacyfluthrin           21c)         (I-1-27) and (2-5) cypermethrin         48c)         (I-1-67) and (2-5) cypermethrin           21d)         (I-1-27) and (2-6) deltamethrin         48d)         (I-1-67) and (2-5) cypermethrin           21e)         (I-1-27) and (2-12) lambda-cyhalothrin         48e)         (I-1-67) and (2-12) lambda-cyhalothrin           21f)         (I-1-27) and (2-14) taufluvalinate         48f)         (I-1-67) and (2-14) taufluvalinate           21g)         (I-1-27) and (2-24) gamma-cyhalothrin         48g)         (I-1-68) and (2-14) taufluvalinate           21g)         (I-1-29) and (2-24) gamma-cyhalothrin         49a)         (I-1-68) and (2-1) acrinathrin           22g)         (I-1-29) and (2-3) betacyfluthrin         49b)         (I-1-68) and (2-3) betacyfluthrin           22d)         (I-1-29) and (2-6) deltamethrin         49c)         (I-1-68) and (2-5) cypermethrin           22e)         (I-1-29) an	20d)	(I-1-26) and (2-6) deltamethrin	47d)	(I-1-66) and (2-6) deltamethrin
(I-1-26) and (2-24) gamma-cyhalothrin   47g)   (I-1-66) and (2-24) gamma-cyhalothrin   48a)   (I-1-67) and (2-1) acrinathrin   48b)   (I-1-67) and (2-3) betacyfluthrin   48c)   (I-1-67) and (2-3) betacyfluthrin   48d)   (I-1-67) and (2-3) betacyfluthrin   48d)   (I-1-67) and (2-5) cypermethrin   48d)   (I-1-67) and (2-6) deltamethrin   48d)   (I-1-67) and (2-6) deltamethrin   48d)   (I-1-67) and (2-12) lambda-cyhalothrin   48f)   (I-1-67) and (2-12) lambda-cyhalothrin   48g)   (I-1-27) and (2-14) taufluvalinate   48g)   (I-1-68) and (2-14) taufluvalinate   49a)   (I-1-68) and (2-3) betacyfluthrin   49c)   (I-1-68) and (2-5) cypermethrin   49d)   (I-1-68) and (2-12) lambda-cyhalothrin   49d)   (I-1-68) and (2-12) lambda-cyhalothrin   49d)   (I-1-68) and (2-12) lambda-cyhalothrin   49d)   (I-1-68) and (2-14) taufluvalinate   49f)   (I-1-68) and (2-14) taufluvalinate   49g)   (I-1-68) and (2-24) gamma-cyhalothrin   49g)   (I-1-68) and (2-24) gamma-cyha	20e)	(I-1-26) and (2-12) lambda-cyhalothrin	47e)	(I-1-66) and (2-12) lambda-cyhalothrin
21a)       (I-1-27) and (2-1) acrinathrin       48a)       (I-1-67) and (2-1) acrinathrin         21b)       (I-1-27) and (2-3) betacyfluthrin       48b)       (I-1-67) and (2-3) betacyfluthrin         21c)       (I-1-27) and (2-5) cypermethrin       48c)       (I-1-67) and (2-5) cypermethrin         21d)       (I-1-27) and (2-6) deltamethrin       48d)       (I-1-67) and (2-6) deltamethrin         21e)       (I-1-27) and (2-12) lambda-cyhalothrin       48e)       (I-1-67) and (2-12) lambda-cyhalothrin         21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-29) and (2-14) acrinathrin       48g)       (I-1-67) and (2-14) taufluvalinate         22g)       (I-1-29) and (2-13) betacyfluthrin       49a)       (I-1-68) and (2-14) gamma-cyhalothrin         22g)       (I-1-29) and (2-3) betacyfluthrin       49c)       (I-1-68) and (2-3) betacyfluthrin         22g)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49f)       (I-1-68) and (2-24) gamma-cyhalothrin	20f)	(I-1-26) and (2-14) taufluvalinate	47f)	(I-1-66) and (2-14) taufluvalinate
21b)       (I-1-27) and (2-3) betacyfluthrin       48b)       (I-1-67) and (2-3) betacyfluthrin         21c)       (I-1-27) and (2-5) cypermethrin       48c)       (I-1-67) and (2-5) cypermethrin         21d)       (I-1-27) and (2-6) deltamethrin       48d)       (I-1-67) and (2-6) deltamethrin         21e)       (I-1-27) and (2-12) lambda-cyhalothrin       48e)       (I-1-67) and (2-12) lambda-cyhalothrin         21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-14) taufluvalinate         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-24) gamma-cyhalothrin       49f)       (I-1-68) and (2-24) gamma-cyhalothrin         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	20g)	(I-1-26) and (2-24) gamma-cyhalothrin	47g)	(I-1-66) and (2-24) gamma-cyhalothrin
21c)       (I-1-27) and (2-5) cypermethrin       48c)       (I-1-67) and (2-5) cypermethrin         21d)       (I-1-27) and (2-6) deltamethrin       48d)       (I-1-67) and (2-6) deltamethrin         21e)       (I-1-27) and (2-12) lambda-cyhalothrin       48e)       (I-1-67) and (2-12) lambda-cyhalothrin         21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-14) taufluvalinate         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-6) deltamethrin       49d)       (I-1-68) and (2-6) deltamethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21a)	(I-1-27) and (2-1) acrinathrin	48a)	(I-1-67) and (2-1) acrinathrin
21d)       (I-1-27) and (2-6) deltamethrin       48d)       (I-1-67) and (2-6) deltamethrin         21e)       (I-1-27) and (2-12) lambda-cyhalothrin       48e)       (I-1-67) and (2-12) lambda-cyhalothrin         21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-14) taufluvalinate         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22e)       (I-1-29) and (2-14) taufluvalinate       49f)       (I-1-68) and (2-14) taufluvalinate         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21b)	(I-1-27) and (2-3) betacyfluthrin	48b)	(I-1-67) and (2-3) betacyfluthrin
21e)       (I-1-27) and (2-12) lambda-cyhalothrin       48e)       (I-1-67) and (2-12) lambda-cyhalothrin         21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-24) gamma-cyhalothrin         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-14) taufluvalinate       49f)       (I-1-68) and (2-14) taufluvalinate         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21c)	(I-1-27) and (2-5) cypermethrin	48c)	(I-1-67) and (2-5) cypermethrin
21f)       (I-1-27) and (2-14) taufluvalinate       48f)       (I-1-67) and (2-14) taufluvalinate         21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-24) gamma-cyhalothrin         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-6) deltamethrin       49d)       (I-1-68) and (2-6) deltamethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21d)	(I-1-27) and (2-6) deltamethrin	48d)	(I-1-67) and (2-6) deltamethrin
21g)       (I-1-27) and (2-24) gamma-cyhalothrin       48g)       (I-1-67) and (2-24) gamma-cyhalothrin         22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-6) deltamethrin       49d)       (I-1-68) and (2-6) deltamethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21e)	(I-1-27) and (2-12) lambda-cyhalothrin	48e)	(I-1-67) and (2-12) lambda-cyhalothrin
22a)       (I-1-29) and (2-1) acrinathrin       49a)       (I-1-68) and (2-1) acrinathrin         22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-6) deltamethrin       49d)       (I-1-68) and (2-6) deltamethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-14) taufluvalinate       49f)       (I-1-68) and (2-14) taufluvalinate         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21f)	(I-1-27) and (2-14) taufluvalinate	48f)	(I-1-67) and (2-14) taufluvalinate
22b)       (I-1-29) and (2-3) betacyfluthrin       49b)       (I-1-68) and (2-3) betacyfluthrin         22c)       (I-1-29) and (2-5) cypermethrin       49c)       (I-1-68) and (2-5) cypermethrin         22d)       (I-1-29) and (2-6) deltamethrin       49d)       (I-1-68) and (2-6) deltamethrin         22e)       (I-1-29) and (2-12) lambda-cyhalothrin       49e)       (I-1-68) and (2-12) lambda-cyhalothrin         22f)       (I-1-29) and (2-14) taufluvalinate       49f)       (I-1-68) and (2-14) taufluvalinate         22g)       (I-1-29) and (2-24) gamma-cyhalothrin       49g)       (I-1-68) and (2-24) gamma-cyhalothrin	21g)	(I-1-27) and (2-24) gamma-cyhalothrin	48g)	(I-1-67) and (2-24) gamma-cyhalothrin
22c) (I-1-29) and (2-5) cypermethrin 22d) (I-1-29) and (2-6) deltamethrin 49d) (I-1-68) and (2-6) deltamethrin 22e) (I-1-29) and (2-12) lambda-cyhalothrin 22f) (I-1-29) and (2-14) taufluvalinate 22g) (I-1-29) and (2-24) gamma-cyhalothrin 49g) (I-1-68) and (2-24) gamma-cyhalothrin 49g) (I-1-68) and (2-24) gamma-cyhalothrin	22a)	(I-1-29) and (2-1) acrinathrin	49a)	(I-1-68) and (2-1) acrinathrin
22d) (I-1-29) and (2-6) deltamethrin 49d) (I-1-68) and (2-6) deltamethrin 22e) (I-1-29) and (2-12) lambda-cyhalothrin 22f) (I-1-29) and (2-14) taufluvalinate 22g) (I-1-29) and (2-24) gamma-cyhalothrin 49g) (I-1-68) and (2-24) gamma-cyhalothrin 29g)	22b)	(I-1-29) and (2-3) betacyfluthrin	49b)	(I-1-68) and (2-3) betacyfluthrin
22e) (I-1-29) and (2-12) lambda-cyhalothrin (I-1-68) and (2-12) lambda-cyhalothrin (I-1-29) and (2-14) taufluvalinate (I-1-68) and (2-14) taufluvalinate (I-1-68) and (2-24) gamma-cyhalothrin (I-1-68) and (2-24) gamma-cyhalothrin	22c)	(I-1-29) and (2-5) cypermethrin	49c)	(I-1-68) and (2-5) cypermethrin
22f) (I-1-29) and (2-14) taufluvalinate 49f) (I-1-68) and (2-14) taufluvalinate 22g) (I-1-29) and (2-24) gamma-cyhalothrin 49g) (I-1-68) and (2-24) gamma-cyhalothrin	22d)	(I-1-29) and (2-6) deltamethrin	49d)	(I-1-68) and (2-6) deltamethrin
22g) (I-1-29) and (2-24) gamma-cyhalothrin 49g) (I-1-68) and (2-24) gamma-cyhalothrin	22e)	(I-1-29) and (2-12) lambda-cyhalothrin	49e)	(I-1-68) and (2-12) lambda-cyhalothrin
	22f)	(I-1-29) and (2-14) taufluvalinate	49f)	(I-1-68) and (2-14) taufluvalinate
23a) (I-1-30) and (2-1) acrinathrin 50a) (I-1-69) and (2-1) acrinathrin	22g)	(I-1-29) and (2-24) gamma-cyhalothrin	49g)	(I-1-68) and (2-24) gamma-cyhalothrin
	23a)	(I-1-30) and (2-1) acrinathrin	50a)	(I-1-69) and (2-1) acrinathrin
23b) (I-1-30) and (2-3) betacyfluthrin 50b) (I-1-69) and (2-3) betacyfluthrin	23b)	(I-1-30) and (2-3) betacyfluthrin	50Ь)	(I-1-69) and (2-3) betacyfluthrin

No.	Active compound combination comprising	No.	Active compound combination comprising
23c)	(I-1-30) and (2-5) cypermethrin	50c)	(I-1-69) and (2-5) cypermethrin
23d)	(I-1-30) and (2-6) deltamethrin	50d)	(I-1-69) and (2-6) deltamethrin
23e)	(I-1-30) and (2-12) lambda-cyhalothrin	50e)	(I-1-69) and (2-12) lambda-cyhalothrin
23f)	(I-1-30) and (2-14) taufluvalinate	50f)	(I-1-69) and (2-14) taufluvalinate
23g)	(I-1-30) and (2-24) gamma-cyhalothrin	50g)	(I-1-69) and (2-24) gamma-cyhalothrin
24a)	(I-1-31) and (2-1) acrinathrin	5la)	(I-1-70) and (2-1) acrinathrin
24b)	(I-1-31) and (2-3) betacyfluthrin	51b)	(I-1-70) and (2-3) betacyfluthrin
24c)	(I-1-31) and (2-5) cypermethrin	51c)	(I-1-70) and (2-5) cypermethrin
24d)	(I-1-31) and (2-6) deltamethrin	51d)	(I-1-70) and (2-6) deltamethrin
24e)	(I-1-31) and (2-12) lambda-cyhalothrin	51e)	(I-1-70) and (2-12) lambda-cyhalothrin
24f)	(I-1-31) and (2-14) taufluvalinate	51f)	(I-1-70) and (2-14) taufluvalinate
24g)	(I-1-31) and (2-24) gamma-cyhalothrin	51g)	(I-1-70) and (2-24) gamma-cyhalothrin
25a)	_ (I-1-32) and (2-1) acrinathrin	52a)	(I-1-71) and (2-1) acrinathrin
25b)	(f-1-32) and (2-3) betacyfluthrin	52b)	(I-1-71) and (2-3) betacyfluthrin
25c)	(I-1-32) and (2-5) cypermethrin	52c)	(I-1-71) and (2-5) cypermethrin
25d)	(I-1-32) and (2-6) deltamethrin	52d)	(I-1-71) and (2-6) deltamethrin
25e)	(I-1-32) and (2-12) lambda-cyhalothrin	52e)	(I-1-71) and (2-12) lambda-cyhalothrin
25f)	(I-1-32) and (2-14) taufluvalinate	52f)	(I-1-71) and (2-14) taufluvalinate
25g)	(I-1-32) and (2-24) gamma-cyhalothrin	52g)	(I-1-71) and (2-24) gamma-cyhalothrin
26a)	(I-1-33) and (2-1) acrinathrin ,	53a)	(I-1-72) and (2-1) acrinathrin
26b)	(I-1-33) and (2-3) betacyfluthrin	53b) ·	(I-1-72) and (2-3) betacyfluthrin
26c)	(I-1-33) and (2-5) cypermethrin	. 53c)	(I-1-72) and (2-5) cypermethrin
26d)	(I-1-33) and (2-6) deltamethrin	53d)	(I-1-72) and (2-6) deltamethrin
26e)	(I-1-33) and (2-12) lambda-cyhalothrin	53e)	(I-1-72) and (2-12) lambda-cyhalothrin
26f)	(I-1-33) and (2-14) taufluvalinate	53f)	(I-1-72) and (2-14) taufluvalinate
26g)	(I-1-33) and (2-24) gamma-cyhalothrin	53g)	(I-1-72) and (2-24) gamma-cyhalothrin
27a)	(I-1-38) and (2-1) acrinathrin		
27b)	(I-1-38) and (2-3) betacyfluthrin		
27c)	(I-1-38) and (2-5) cypermethrin		•
27d)	(I-1-38) and (2-6) deltamethrin		
27e)	(I-1-38) and (2-12) lambda-cyhalothrin		
27f)	(I-1-38) and (2-14) taufluvalinate		
27g)	(I-1-38) and (2-24) gamma-cyhalothrin		

However, the general or preferred radical definitions or illustrations listed above can also be combined with one another as desired, i.e. between their respective ranges and preferred ranges. The definitions apply to the end products and, correspondingly, to precursors and intermediates.

10

15

25

Preference according to the invention is given to active compound combinations comprising compounds of the formula (I) and pyrethroids of the formulae (2-1) to (2-24), where the individual radicals are a combination of the meanings listed above as being preferred (preferable).

Particular preference according to the invention is given to active compound combinations comprising compounds of the formula (I) and pyrethroids of the formulae (2-1) to (2-24), where the individual radicals are a combination of the meanings listed above as being particularly preferred.

Very particular preference according to the invention is given to active compound combinations comprising compounds of the formula (I) and pyrethroids of the formulae (2-1) to (2-24), where the individual radicals are a combination of the meanings listed above as being very particularly preferred.

Saturated or unsaturated hydrocarbon radicals, such as alkyl or alkenyl, can in each case be straightchain or branched as far as this is possible, including in combination with heteroatoms, such as, for example, in alkoxy.

Optionally substituted radicals can be mono- or polysubstituted, where in the case of polysubstitution the substituents can be identical or different.

In addition, the active compound combinations may also comprise further fungicidally, acaricidally or insecticidally active additives.

If the active compounds in the active compound combinations according to the invention are present in certain weight ratios, the synergistic effect is particularly pronounced. However, the weight ratios of the active compounds in the active compound combinations can be varied within a relatively wide range. In general, the combinations according to the invention comprise active compounds of the formula (I) and the mixing partner of the group 2 in the preferred and particularly preferred mixing ratios given:

the mixing ratios are based on weight ratios. The ratio is to be understood as meaning active compound of the formula (I):mixing partner

Mixing partner	Preferred mixing ratio	Particularly preferred mixing ratio
Acrinathrin	20:1 to 1:50	10:1 to 1:1
Alpha-Cypermethrin	50:1 to 1:5	10:1 to 1:1
Betacyfluthrin	50:1 to 1:5	10:1 to 1:1

Mixing partner	Preferred mixing ratio	Particularly preferred mixing ratio
cyhalothrin	50:1 to 1:5	10:1 to 1:1
cypermethrin	50:1 to 1:5	10:1 to 1:1
deltamethrin	50:1 to 1:5	10:1 to 1:1
esfenvalerate	50:1 to 1:5	10:1 to 1:1
etofenprox	10:1 to 1:10	5:1 to 1:5
fenpropathrin	10:1 to 1:10	5:1 to 1:5
fenvalerate	20:1 to 1:5	10:1 to 1:1
flucythrinate	50:1 to 1:5	10:1 to 1:1
lambda-cyhalothrin	50:1 to 1:5	10:1 to 1:1
permethrin	10:1 to 1:10	5:1 to 1:5
tau-fluvalinate	20:1 to 1:5	10:1 to 1:2
tralomethrin	50:1 to 1:5	10:1 to 1:1
zeta-cypermethrin	50:1 to 1:5	10:1 to 1:2
cyfluthrin	50:1 to 1:5	10:1 to 1:1
bifenthrin	10:1 to 1:10	10:1 to 1:1
cycloprothrin	10:1 to 1:10	5:1 to 1:5
eflusilanate	10:1 to 1:10	5:1 to 1:5
fubfenprox	10:1 to 1:10	5:1 to 1:5
pyrethrin	50:1 to 1:10	5:1 to 1:1
resmethrin	50:1 to 1:10	5:1 to 1:1
gamma-cyhalothrin	50:1 to 1:5	10:1 to 1:1

The active compound combinations according to the invention are suitable for controlling animal pests, preferably arthropods and nematodes, in particular insects and arachnids, found in agriculture, in animal health, in forests, in the protection of stored products and materials and in the hygiene sector. They are active against normally sensitive and resistant species, and against all or individual developmental stages. The abovementioned pests include:

From the order of the Isopoda, for example, Oniscus asellus, Armadillidium vulgare, Porcellio scaber. From the order of the Diplopoda, for example, Blaniulus guttulatus.

From the order of the Chilopoda, for example, Geophilus carpophagus, Scutigera spp. From the order of the Symphyla, for example, Scutigerella immaculata. From the order of the Thysanura, for example, Lepisma saccharina.

From the order of the Collembola, for example, Onychiurus armatus.

From the order of the Orthoptera, for example, Acheta domesticus, Gryllotalpa spp., Locusta migratoria migratorioides, Melanoplus spp., Schistocerca gregaria.

From the order of the Blattaria, for example, Blatta orientalis, Periplaneta americana, Leucophaea maderae, Blattella germanica.

5 From the order of the Dermaptera, for example, Forficula auricularia.

From the order of the Isoptera, for example, Reticulitermes spp.

From the order of the Phthiraptera, for example, Pediculus humanus corporis, Haematopinus spp., Linognathus spp., Trichodectes spp., Damalinia spp.

From the order of the Thysanoptera, for example, Hercinothrips femoralis, Thrips tabaci, Thrips palmi, Frankliniella occidentalis.

From the order of the Heteroptera, for example, Eurygaster spp., Dysdercus intermedius, Piesma quadrata, Cimex lectularius, Rhodnius prolixus, Triatoma spp.

From the order of the Homoptera, for example, Aleurodes brassicae, Bemisia tabaci, Trialeurodes vaporariorum, Aphis gossypii, Brevicoryne brassicae, Cryptomyzus ribis, Aphis fabae, Aphis pomi, Eriosoma lanigerum, Hyalopterus arundinis, Phylloxera vastatrix, Pemphigus spp., Macrosiphum avenae, Myzus spp., Phorodon humuli, Rhopalosiphum padi, Empoasca spp., Euscelis bilobatus, Nephotettix cincticeps, Lecanium corni, Saissetia oleae, Laodelphax striatellus, Nilaparvata lugens,

Aonidiella aurantii, Aspidiotus hederae, Pseudococcus spp., Psylla spp.

From the order of the Lepidoptera, for example, Pectinophora gossypiella, Bupalus piniarius, Cheimatobia brumata, Lithocolletis blancardella, Hyponomeuta padella, Plutella xylostella, Malacosoma neustria, Euproctis chrysorrhoea, Lymantria spp., Bucculatrix thurberiella, Phyllocnistis citrella, Agrotis spp., Euxoa spp., Feltia spp., Earias insulana, Heliothis spp., Mamestra brassicae, Panolis flammea, Spodoptera spp., Trichoplusia ni, Carpocapsa pomonella, Pieris spp., Chilo spp., Pyrausta nubilalis, Ephestia kuehniella, Galleria mellonella, Tineola bisselliella, Tinea pellionella, Hofmannophila pseudospretella, Cacoecia podana, Capua reticulana, Choristoneura fumiferana,

Hofmannophila pseudospretella, Cacoecia podana, Capua reticulana, Choristoneura fumiferana, Clysia ambiguella, Homona magnanima, Tortrix viridana, Cnaphalocerus spp., Oulema oryzae.

From the order of the Coleoptera, for example, Anobium punctatum, Rhizopertha dominica, Bruchidius obtectus, Acanthoscelides obtectus, Hylotrupes bajulus, Agelastica alni, Leptinotarsa decemlineata, Phaedon cochleariae, Diabrotica spp., Psylliodes chrysocephala, Epilachna varivestis,

Atomaria spp., Oryzaephilus surinamensis, Anthonomus spp., Sitophilus spp., Otiorrhynchus sulcatus, Cosmopolites sordidus, Ceuthorrhynchus assimilis, Hypera postica, Dermestes spp., Trogoderma spp., Anthrenus spp., Attagenus spp., Lyctus spp., Meligethes aeneus, Ptinus spp., Niptus hololeucus, Gibbium psylloides, Tribolium spp., Tenebrio molitor, Agriotes spp., Conoderus spp., Melolontha melolontha, Amphimallon solstitialis, Costelytra zealandica, Lissorhoptrus

35 oryzophilus.

30

10

15

20

30

35

From the order of the Hymenoptera, for example, Diprion spp., Hoplocampa spp., Lasius spp., Monomorium pharaonis, Vespa spp.

From the order of the Diptera, for example, Aedes spp., Anopheles spp., Culex spp., Drosophila melanogaster, Musca spp., Fannia spp., Calliphora erythrocephala, Lucilia spp., Chrysomyia spp.,

Cuterebra spp., Gastrophilus spp., Hyppobosca spp., Stomoxys spp., Oestrus spp., Hypoderma spp., Tabanus spp., Tannia spp., Bibio hortulanus, Oscinella frit, Phorbia spp., Pegomyia hyoscyami, Ceratitis capitata, Dacus oleae, Tipula paludosa, Hylemyia spp., Liriomyza spp.

From the order of the Siphonaptera, for example, Xenopsylla cheopis, Ceratophyllus spp.

From the class of the Arachnida, for example, Scorpio maurus, Latrodectus mactans, Acarus siro,
Argas spp., Ornithodoros spp., Dermanyssus gallinae, Eriophyes ribis, Phyllocoptruta oleivora,
Boophilus spp., Rhipicephalus spp., Amblyomma spp., Hyalomma spp., Ixodes spp., Psoroptes spp.,
Chorioptes spp., Sarcoptes spp., Tarsonemus spp., Bryobia praetiosa, Panonychus spp., Tetranychus spp., Hemitarsonemus spp., Brevipalpus spp.

The plant-parasitic nematodes include, for example, Pratylenchus spp., Radopholus similis, Ditylenchus dipsaci, Tylenchulus semipenetrans, Heterodera spp., Globodera spp., Meloidogyne spp., Aphelenchoides spp., Longidorus spp., Xiphinema spp., Trichodorus spp., Bursaphelenchus spp.

The active compound combinations can be converted into the customary formulations such as solutions, emulsions, wettable powders, suspensions, powders, dusts, pastes, soluble powders, granules, suspension-emulsion concentrates, natural and synthetic materials impregnated with active compound, and microencapsulations in polymeric materials.

These formulations are produced in a known manner, for example by mixing the active compounds with extenders, that is, liquid solvents and/or solid carriers, optionally with the use of surfactants, that is, emulsifiers and/or dispersants, and/or foam formers.

If the extender used is water, it is also possible, for example, to use organic solvents as cosolvents. The following are essentially suitable as liquid solvents: aromatics such as xylene, toluene or alkylnaphthalenes, chlorinated aromatics or chlorinated aliphatic hydrocarbons such as chlorobenzenes, chloroethylenes or methylene chloride, aliphatic hydrocarbons such as cyclohexane or paraffins, for example mineral oil fractions, mineral and vegetable oils, alcohols such as butanol or glycol and their ethers and esters, ketones such as acetone, methyl ethyl ketone, methyl isobutyl ketone or cyclohexanone, strongly polar solvents such as dimethylformamide and dimethyl sulfoxide, or else water.

Suitable solid carriers are:

for example ammonium salts and ground natural minerals such as kaolins, clays, talc, chalk, quartz, attapulgite, montmorillonite or diatomaceous earth, and ground synthetic materials such as highly disperse silica, alumina and silicates; suitable solid carriers for granules are: for example crushed and fractionated natural rocks such as calcite, marble, pumice, sepiolite and dolomite, or else synthetic granules of inorganic and organic meals, and granules of organic material such as sawdust, coconut shells, corn cobs and tobacco stalks; suitable emulsifiers and/or foam formers are: for example nonionic and anionic emulsifiers such as polyoxyethylene fatty acid esters, polyoxyethylene fatty alcohol ethers, for example alkylaryl polyglycol ethers, alkylsulfonates, alkyl sulfates, arylsulfonates, or else protein hydrolysates; suitable dispersants are: for example lignosulfite waste liquors and methylcellulose.

Tackifiers such as carboxymethylcellulose and natural and synthetic polymers in the form of powders, granules or latices, such as gum arabic, polyvinyl alcohol and polyvinyl acetate, or else natural phospholipids such as cephalins and lecithins and synthetic phospholipids can be used in the formulations. Other possible additives are mineral and vegetable oils.

It is possible to use colorants such as inorganic pigments, for example iron oxide, titanium oxide and Prussian Blue, and organic colorants such as alizarin colorants, azo colorants and metal phthalocyanine colorants, and trace nutrients such as salts of iron, manganese, boron, copper, cobalt, molybdenum and zinc.

The formulations generally comprise between 0.1 and 95% by weight of active compound, preferably between 0.5 and 90%.

25

30

20

5

10

15

The active compound combinations according to the invention can be present in their commercially available formulations and in the use forms, prepared from these formulations, as a mixture with other active compounds, such as insecticides, attractants, sterilants, bactericides, acaricides, nematicides, fungicides, growth-regulating substances or herbicides. The insecticides include, for example, phosphates, carbamates, carboxylates, chlorinated hydrocarbons, phenylureas and substances produced by microorganisms, inter alia.

Mixtures with other known active compounds such as herbicides or with fertilizers and growth regulators are also possible.

When used as insecticides, the active compound combinations according to the invention can furthermore be present in their commercially available formulations and in the use forms, prepared from these formulations, as a mixture with synergists. Synergists are compounds which increase the action of the active compounds, without it being necessary for the synergist added to be active itself.

5

The active compound content of the use forms prepared from the commercially available formulations can vary within wide limits. The active compound concentration of the use forms can be from 0.0000001 to 95% by weight of active compound, preferably between 0.0001 and 1% by weight.

10 The compounds are employed in a customary manner appropriate for the use forms.

When used against hygiene pests and stored-product pests, the active compound combinations are distinguished by an excellent residual action on wood and clay as well as good stability to alkali on limed substrates.

15

35

The active compound combinations according to the invention are not only active against plant pests, hygiene pests and stored-product pests, but also, in the veterinary medicine sector, against animal parasites (ectoparasites) such as hard ticks, soft ticks, mange mites, harvest mites, flies (stinging and licking), parasitizing fly larvae, lice, head lice, bird lice and fleas. These parasites include:

From the order of the Anoplurida, for example, Haematopinus spp., Linognathus spp., Pediculus spp., Phtirus spp., Solenopotes spp.

From the order of the Mallophagida and the suborders Amblycerina and Ischnocerina, for example, Trimenopon spp., Menopon spp., Trinoton spp., Bovicola spp., Werneckiella spp., Lepikentron spp., Damalina spp., Trichodectes spp., Felicola spp.

From the order Diptera and the suborders Nematocerina and Brachycerina, for example, Aedes spp., Anopheles spp., Culex spp., Simulium spp., Eusimulium spp., Phlebotomus spp., Lutzomyia spp., Culicoides spp., Chrysops spp., Hybomitra spp., Atylotus spp., Tabanus spp., Haematopota spp., Philipomyia spp., Braula spp., Musca spp., Hydrotaea spp., Stomoxys spp., Haematobia spp., Morellia spp., Fannia spp., Glossina spp., Calliphora spp., Lucilia spp., Chrysomyia spp., Wohlfahrtia spp., Sarcophaga spp., Oestrus spp., Hypoderma spp., Gasterophilus spp., Hippobosca spp., Lipoptena spp., Melophagus spp.

From the order of the Siphonapterida, for example, Pulex spp., Ctenocephalides spp., Xenopsylla spp., Ceratophyllus spp.

From the order of the Heteropterida, for example, Cimex spp., Triatoma spp., Rhodnius spp., Panstrongylus spp.

From the order of the Blattarida, for example, Blatta orientalis, Periplaneta americana, Blattella germanica, Supella spp.

From the subclass of the Acaria (Acarida) and the orders of the Meta- and Mesostigmata, for example, Argas spp., Ornithodorus spp., Otobius spp., Ixodes spp., Amblyomma spp., Boophilus spp.,

Dermacentor spp., Haemophysalis spp., Hyalomma spp., Rhipicephalus spp., Dermanyssus spp., Raillietia spp., Pneumonyssus spp., Sternostoma spp., Varroa spp.

From the order of the Actinedida (Prostigmata) and Acaridida (Astigmata), for example, Acarapis spp., Cheyletiella spp., Ornithocheyletia spp., Myobia spp., Psorergates spp., Demodex spp., Trombicula spp., Listrophorus spp., Acarus spp., Tyrophagus spp., Caloglyphus spp., Hypodectes spp., Pterolichus spp., Psoroptes spp., Chorioptes spp., Otodectes spp., Sarcoptes spp., Notoedres spp., Knemidocoptes spp., Cytodites spp., Laminosioptes spp.

The active-compound combinations according to the invention are also suitable for controlling arthropods which attack agricultural livestock such as, for example, cattle, sheep, goats, horses, pigs, donkeys, camels, buffaloes, rabbits, chickens, turkeys, ducks, geese, honey-bees, other domestic animals such as, for example, dogs, cats, caged birds, aquarium fish and so-called experimental animals such as, for example, hamsters, guinea pigs, rats and mice. By controlling these arthropods, cases of death and reductions in productivity (for meat, milk, wool, hides, eggs, honey and the like) should be diminished, so that more economical and simpler animal husbandry is possible by the use of the active compound combinations according to the invention.

The active compound combinations according to the invention are used in the veterinary sector in a known manner by enteral administration in the form of, for example, tablets, capsules, potions, drenches, granules, pastes, boluses, the feed-through method, suppositories, by parenteral administration such as, for example, by injections (intramuscularly, subcutaneously, intravenously, intraperitoneally and the like), implants, by nasal administration, by dermal administration in the form of, for example, immersing or dipping, spraying, pouring-on, spotting-on, washing, dusting, and with the aid of active-compound-comprising molded articles such as collars, ear tags, tail tags, limb bands, halters, marking devices and the like.

30

5

10

15

20

25

When used for cattle, poultry, domestic animals and the like, the active compound combinations can be applied as formulations (for example powders, emulsions, flowables) comprising the active compounds in an amount of 1 to 80% by weight, either directly or after 100- to 10 000-fold dilution, or they may be used as a chemical dip.

10

35

Moreover, it has been found that the active compound combinations according to the invention show a potent insecticidal action against insects which destroy industrial materials.

The following insects may be mentioned by way of example and with preference, but not by way of limitation:

Beetles such as Hylotrupes bajulus, Chlorophorus pilosis, Anobium punctatum, Xestobium rufovillosum, Ptilinus pecticornis, Dendrobium pertinex, Ernobius mollis, Priobium carpini, Lyctus brunneus, Lyctus africanus, Lyctus planicollis, Lyctus linearis, Lyctus pubescens, Trogoxylon aequale, Minthes rugicollis, Xyleborus spec., Tryptodendron spec., Apate monachus, Bostrychus capucins, Heterobostrychus brunneus, Sinoxylon spec., Dinoderus minutus.

Dermapterans such as Sirex juvencus, Urocerus gigas, Urocerus gigas taignus, Urocerus augur.

Termites such as Kalotermes flavicollis, Cryptotermes brevis, Heterotermes indicola, Reticulitermes flavipes, Reticulitermes santonensis, Reticulitermes lucifugus, Mastotermes darwiniensis, Zootermopsis nevadensis, Coptotermes formosanus.

15 Bristle-tails such as Lepisma saccharina.

Industrial materials in the present context are understood as meaning non-living materials such as, preferably, polymers, adhesives, glues, paper and board, leather, wood, timber products and paints.

The material which is to be protected from insect attack is very particularly preferably wood and timber products.

Wood and timber products which can be protected by the composition according to the invention, or mixtures comprising it, are to be understood as meaning, for example:

- 25 Construction timber, wooden beams, railway sleepers, bridge components, jetties, vehicles made of wood, boxes, pallets, containers, telephone poles, wood lagging, windows and doors made of wood, plywood, chipboard, joinery, or timber products which quite generally are used in house construction or building joinery.
- The active compound combinations can be used as such, in the form of concentrates or generally customary formulations such as powders, granules, solutions, suspensions, emulsions or pastes.

The abovementioned formulations can be prepared in a manner known per se, for example by mixing the active compounds with at least one solvent or diluent, emulsifier, dispersant and/or binder or fixative, water repellant, if desired desiccants and UV stabilizers, and if desired colorants and pigments and other processing auxiliaries.

The insecticidal compositions or concentrates used for protecting wood and timber products comprise the active compound according to the invention in a concentration of 0.0001 to 95% by weight, in particular 0.001 to 60% by weight.

5

10

The amount of composition or concentrate employed depends on the species and the abundance of the insects and on the medium. The optimal quantity to be employed can be determined in each case by test series upon application. In general, however, it will suffice to employ 0.0001 to 20% by weight, preferably 0.001 to 10% by weight, of the active compound, based on the material to be protected.

A suitable solvent and/or diluent is an organochemical solvent or solvent mixture and/or an oily or oil-type organochemical solvent or solvent mixture of low volatility and/or a polar organochemical solvent or solvent mixture and/or water and, if appropriate, an emulsifier and/or wetter.

15

Organochemical solvents which are preferably employed are oily or oil-type solvents with an evaporation number of above 35 and a flash point of above 30°C, preferably above 45°C. Such oily and oil-type solvents which are insoluble in water and of low volatility and which are used are suitable mineral oils or their aromatic fractions or mineral-oil-containing solvent mixtures, preferably white spirit, petroleum and/or alkylbenzene.

20

Mineral oils with a boiling range of 170 to 220°C, white spirit with a boiling range of 170 to 220°C, spindle oil with a boiling range of 250 to 350°C, petroleum and aromatics with a boiling range of 160 to 280°C, oil of turpentine, and the like are advantageously used.

25

In a preferred embodiment, liquid aliphatic hydrocarbons with a boiling range of 180 to 210°C or high-boiling mixtures of aromatic and aliphatic hydrocarbons with a boiling range of 180 to 220°C and/or spindle oil and/or monochloronaphthalene, preferably α-monochloronaphthalene, are used.

30

The organic oily or oil-type solvents of low volatility and with an evaporation number of above 35 and a flash point of above 30°C, preferably above 45°C, can be replaced in part by organochemical solvents of high or medium volatility, with the proviso that the solvent mixture also has an evaporation number of above 35 and a flash point of above 30°C, preferably above 45°C, and that the mixture is soluble or emulsifiable in this solvent mixture.

In a preferred embodiment, some of the organochemical solvent or solvent mixture or an aliphatic polar organochemical solvent or solvent mixture is replaced. Aliphatic organochemical solvents which contain hydroxyl and/or ester and/or ether groups are preferably used, such as, for example, glycol ethers, esters or the like.

5

10

Organochemical binders used for the purposes of the present invention are the synthetic resins and/or binding drying oils which are known per se and which can be diluted in water and/or dissolved or dispersed or emulsified in the organochemical solvents employed, in particular binders composed of, or comprising, an acrylate resin, a vinyl resin, for example polyvinyl acetate, polyester resin, polycondensation or polyaddition resin, polyurethane resin, alkyd resin or modified alkyd resin, phenol resin, hydrocarbon resin such as indene/cournarone resin, silicone resin, drying vegetable and/or drying oils and/or physically drying binders based on a natural and/or synthetic resin.

=

The synthetic resin employed as binder can be employed in the form of an emulsion, dispersion or solution. Bitumen or bituminous substances may also be used as binders, in amounts of up to 10% by weight. In addition, colorants, pigments, water repellants, odor-masking agents, and inhibitors or anticorrosive agents and the like, all of which are known per se, can be employed.

20

15 .

In accordance with the invention, the composition or the concentrate preferably comprises, as organochemical binders, at least one alkyd resin or modified alkyd resin and/or a drying vegetable oil. Alkyd resins which are preferably used in accordance with the invention are those with an oil content of over 45% by weight, preferably 50 to 68% by weight.

. 25 Some or all of the abovementioned binder can be replaced by a fixative (mixture) or plasticizer (mixture). These additives are intended to prevent volatilization of the active compounds, and also crystallization or precipitation. They preferably replace 0.01 to 30% of the binder (based on 100% of binder employed).

30

The plasticizers are from the chemical classes of the phthalic esters, such as dibutyl phthalate, dioctyl phthalate or benzyl butyl phthalate, phosphoric esters such as tributyl phosphate, adipic esters such as di(2-ethylhexyl) adipate, stearates such as butyl stearate or amyl stearate, oleates such as butyl oleate, glycerol ethers or higher-molecular-weight glycol ethers, glycerol esters and p-toluenesulfonic esters.

35

Fixatives are based chemically on polyvinyl alkyl ethers such as, for example, polyvinyl methyl ether, or ketones such as benzophenone and ethylenebenzophenone.

Other suitable solvents or diluents are, in particular, water, if appropriate as a mixture with one or more of the abovementioned organochemical solvents or diluents, emulsifiers and dispersants.

Particularly effective timber protection is achieved by industrial-scale impregnating processes, for example the vacuum, double-vacuum or pressure processes.

The active compound combinations according to the invention can equally be employed for protecting objects which come into contact with saltwater or brackish water, in particular hulls, screens, nets, buildings, quaysides and signaling systems, against fouling.

10

15

5

Fouling by sessile Oligochaeta, such as Serpulidae, and by shells and species from the Ledamorpha group (goose barnacles), such as various Lepas and Scalpellum species, or by species from the Balanomorpha group (acorn barnacles), such as Balanus or Pollicipes species, increases the frictional drag of ships and, as a consequence, leads to a marked increase in operation costs owing to higher energy consumption and additionally frequent stops in the dry dock.

Apart from fouling by algae, for example Ectocarpus sp. and Ceramium sp., in particular fouling by sessile Entomostraka groups, which come under the generic term Cirripedia (cirriped crustaceans), is of particular importance.

. 20

Surprisingly, it has now been found that the active compound combinations according to the invention have an outstanding antifouling action.

25

Use of the active compound combinations according to the invention allows the use of heavy metals such as, for example, in bis(trialkyltin) sulfides, tri-n-butyltin laurate, tri-n-butyltin chloride, copper(I) oxide, triethyltin chloride, tri-n-butyl(2-phenyl-4-chlorophenoxy)tin, tributyltin oxide, molybdenum disulfide, antimony oxide, polymeric butyl titanate, phenyl (bispyridine)bismuth chloride, tri-n-butyltin fluoride, manganese ethylenebisthiocarbamate, zinc dimethyldithiocarbamate, zinc ethylenebisthiocarbamate, zinc salts and copper salts of 2-pyridinethiol 1-oxide, bisdimethyl-dithiocarbamoylzinc ethylenebisthiocarbamate, zinc oxide, copper(I) ethylenebisdithiocarbamate, copper thiocyanate, copper naphthenate and tributyltin halides to be dispensed with, or the concentration of these compounds to be substantially reduced.

30

35

If appropriate, the ready-to-use antifouling paints can additionally comprise other active compounds, preferably algicides, fungicides, herbicides, molluscicides, or other antifouling active compounds.

10

15

25

30

Preferable suitable combination partners for the antifouling compositions according to the invention are:

algicides such as 2-tert-butylamino-4-cyclopropylamino-6-methylthio-1,3,5-triazine, dichlorophen, diuron, endothal, fentin acetate, isoproturon, methabenzthiazuron, oxyfluorfen, quinoclamine and terbutryn;

fungicides such as benzo[b]thiophenecarboxylic acid cyclohexylamide S,S-dioxide, dichlofluanid, fluorfolpet, 3-iodo-2-propynyl butylcarbamate, tolylfluanid and azoles such as azaconazole, cyproconazole, epoxyconazole, hexaconazole, metconazole, propiconazole and tebuconazole;

molluscicides such as fentin acetate, metaldehyde, methiocarb, niclosamid, thiodicarb and trimethacarb;

or conventional antifouling active compounds such as 4,5-dichloro-2-octyl-4-isothiazolin-3-one, diiodomethylparatryl sulfone, 2-(N,N-dimethylthiocarbamoylthio)-5-nitrothiazyl, potassium salts, copper salts, sodium salts and zinc salts of 2-pyridinethiol 1-oxide, pyridine-triphenylborane, tetrabutyldistannoxane, 2,3,5,6-tetrachloro-4-(methylsulfonyl)pyridine, 2,4,5,6-tetrachloroisophthalonitrile, tetramethylthiuram disulfide and 2,4,6-trichlorophenylmaleimide.

The antifouling compositions used comprise the active compound combinations according to the invention in a concentration of 0.001 to 50% by weight, in particular 0.01 to 20% by weight.

Moreover, the antifouling compositions according to the invention comprise the customary components such as, for example, those described in Ungerer, *Chem. Ind.* 1985, 37, 730-732 and Williams, Antifouling Marine Coatings, Noyes, Park Ridge, 1973.

Besides the algicidal, fungicidal, molluscicidal active compounds and insecticidal active compounds according to the invention, antifouling paints comprise, in particular, binders.

Examples of recognized binders are polyvinyl chloride in a solvent system, chlorinated rubber in a solvent system, acrylic resins in a solvent system, in particular in an aqueous system, vinyl chloride/vinyl acetate copolymer systems in the form of aqueous dispersions or in the form of organic solvent systems, butadiene/styrene/acrylonitrile rubbers, drying oils such as linseed oil, resin esters or modified hardened resins in combination with tar or bitumen, asphalt and epoxy compounds, small amounts of chlorine rubber, chlorinated polypropylene and vinyl resins.

If appropriate, paints also comprise inorganic pigments, organic pigments or colorants which are preferably insoluble in seawater. Paints may furthermore comprise materials such as colophonium to allow controlled release of the active compounds. Furthermore, the paints may comprise plasticizers,

modifiers which affect the rheological properties and other conventional constituents. The compounds according to the invention or the abovementioned mixtures may also be incorporated into self-polishing antifouling systems.

- The active compound combinations are also suitable for controlling animal pests, in particular insects, arachnids and mites, which are found in enclosed spaces such as, for example, dwellings, factory halls, offices, vehicle cabins and the like. They can be employed in domestic insecticide products for controlling these pests. They are active against sensitive and resistant species and against all developmental stages. These pests include:
- 10 From the order of the Scorpionidea, for example, Buthus occitanus.

From the order of the Acarina, for example, Argas persicus, Argas reflexus, Bryobia ssp., Dermanyssus gallinae, Glyciphagus domesticus, Ornithodorus moubat, Rhipicephalus sanguineus, Trombicula alfreddugesi, Neutrombicula autumnalis, Dermatophagoides pteronissimus, Dermatophagoides forinae.

15 From the order of the Araneae, for example, Aviculariidae, Araneidae.

From the order of the Opiliones, for example, Pseudoscorpiones chelifer, Pseudoscorpiones cheiridium, Opiliones phalangium.

From the order of the Isopoda, for example, Oniscus asellus, Porcellio scaber.

From the order of the Diplopoda, for example, Blaniulus guttulatus, Polydesmus spp.

From the order of the Chilopoda, for example, Geophilus spp.

25

From the order of the Zygentoma, for example, Ctenolepisma spp., Lepisma saccharina, Lepismodes inquilinus.

From the order of the Blattaria, for example, Blatta orientalies, Blattella germanica, Blattella asahinai, Leucophaea maderae, Panchlora spp., Parcoblatta spp., Periplaneta australasiae, Periplaneta americana, Periplaneta brunnea, Periplaneta fuliginosa, Supella longipalpa.

From the order of the Saltatoria, for example, Acheta domesticus.

From the order of the Dermaptera, for example, Forficula auricularia.

From the order of the Isoptera, for example, Kalotermes spp., Reticulitermes spp.

From the order of the Psocoptera, for example, Lepinatus spp., Liposcelis spp.

From the order of the Coleptera, for example, Anthrenus spp., Attagenus spp., Dermestes spp., Latheticus oryzae, Necrobia spp., Ptinus spp., Rhizopertha dominica, Sitophilus granarius, Sitophilus oryzae, Sitophilus zeamais, Stegobium paniceum.

From the order of the Diptera, for example, Aedes aegypti, Aedes albopictus, Aedes taeniorhynchus, Anopheles spp., Calliphora erythrocephala, Chrysozona pluvialis, Culex quinquefasciatus, Culex

pipiens, Culex tarsalis, Drosophila spp., Fannia canicularis, Musca domestica, Phlebotomus spp., Sarcophaga carnaria, Simulium spp., Stomoxys calcitrans, Tipula paludosa.

15

20

25

From the order of the Lepidoptera, for example, Achroia grisella, Galleria mellonella, Plodia interpunctella, Tinea cloacella, Tinea pellionella, Tineola bisselliella.

From the order of the Siphonaptera, for example, Ctenocephalides canis, Ctenocephalides felis, Pulex irritans, Tunga penetrans, Xenopsylla cheopis.

From the order of the Hymenoptera, for example, Camponotus herculeanus, Lasius fuliginosus, Lasius niger, Lasius umbratus, Monomorium pharaonis, Paravespula spp., Tetramorium caespitum. From the order of the Anoplura, for example, Pediculus humanus capitis, Pediculus humanus corporis, Phthirus pubis.

From the order of the Heteroptera, for example, Cimex hemipterus, Cimex lectularius, Rhodnius prolixus, Triatoma infestans.

They are used as aerosols, pressureless spray products, for example pump and atomizer sprays, automatic fogging systems, foggers, foams, gels, evaporator products with evaporator tablets made of cellulose or polymer, liquid evaporators, gel and membrane evaporators, propeller-driven evaporators, energy-free, or passive, evaporation systems, moth papers, moth bags and moth gels, as granules or dusts, in baits for spreading or in bait stations.

According to the invention, it is possible to treat all plants and parts of plants. Plants are to be understood here as meaning all plants and plant populations such as desired and undesired wild plants or crop plants (including naturally occurring crop plants). Crop plants can be plants which can be obtained by conventional breeding and optimization methods or by biotechnological and genetic engineering methods or combinations of these methods, including the transgenic plants and including the plant cultivars which can or cannot be protected by plant breeders' certificates. Parts of plants are to be understood as meaning all above-ground and below-ground parts and organs of plants, such as shoot, leaf, flower and root, examples which may be mentioned being leaves, needles, stems, trunks, flowers, fruit-bodies, fruits and seeds and also roots, tubers and rhizomes. Parts of plants also include harvested plants and vegetative and generative propagation material, for example seedlings, tubers, rhizomes, cuttings and seeds.

The treatment according to the invention of the plants and parts of plants with the active compounds is carried out directly or by action on their environment, habitat or storage area according to customary treatment methods, for example by dipping, spraying, evaporating, atomizing, broadcasting, brushing-on and, in the case of propagation material, in particular in the case of seeds, furthermore by one- or multi-layer coating.

15

20

25

30

. 35

As already mentioned above, it is possible to treat all plants and their parts according to the invention. In a preferred embodiment, wild plant species and plant cultivars, or those obtained by conventional biological breeding methods, such as crossing or protoplast fusion, and parts thereof, are treated. In a further preferred embodiment, transgenic plants and plant cultivars obtained by genetic engineering methods, if appropriate in combination with conventional methods (Genetically Modified Organisms), and parts thereof are treated. The terms "parts", "parts of plants" and "plant parts" have been explained above.

Particularly preferably, plants of the plant cultivars which are in each case commercially available or in use are treated according to the invention.

Depending on the plant species or plant cultivars, their location and growth conditions (soils, climate, vegetation period, diet), the treatment according to the invention may also result in superadditive ("synergistic") effects. Thus, for example, reduced application rates and/or a widening of the activity spectrum and/or an increase in the activity of the substances and compositions which can be used according to the invention, better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products are possible which exceed the effects which were actually to be expected.

The transgenic plants or plant cultivars (i.e. those obtained by genetic engineering) which are preferred and to be treated according to the invention include all plants which, in the genetic modification, received genetic material which imparts particularly advantageous useful traits to these plants. Examples of such traits are better plant growth, increased tolerance to high or low temperatures, increased tolerance to drought or to water or soil salt content, increased flowering performance, easier harvesting, accelerated maturation, higher harvest yields, better quality and/or a higher nutritional value of the harvested products, better storage stability and/or processability of the harvested products. Further and particularly emphasized examples of such properties are a better defense of the plants against animal and microbial pests, such as against insects, mites, phytopathogenic fungi, bacteria and/or viruses, and also increased tolerance of the plants to certain herbicidally active compounds. Examples of transgenic plants which may be mentioned are the important crop plants, such as cereals (wheat, rice), corn, soya beans, potatoes, cotton, tobacco, oilseed rape and also fruit plants (with the fruits apples, pears, citrus fruits and grapes), and particular emphasis is given to corn, soya beans, potatoes, cotton, tobacco and oilseed rape. Traits that are particularly emphasized are the increased defense of the plants against insects, arachnids, nematodes

10

15

20

25

30

and slugs and snails by toxins formed in the plants, in particular those formed by the genetic material from Bacillus thuringiensis (for example by the genes CryIA(a), CryIA(b), CryIA(c), CryIIA, CryIIIA, CryIIIB2, Cry9c Cry2Ab, Cry3Bb and CryIF and also combinations thereof) (hereinbelow referred to as "Bt plants"). Traits that are also particularly emphasized are the increased defense of the plants against fungi, bacteria and viruses by Systemic Acquired Resistance (SAR), systemin, phytoalexins, elicitors, as well as resistance genes and correspondingly expressed proteins and toxins. Traits that are furthermore particularly emphasized are the increased tolerance of the plants to certain herbicidally active compounds, for example imidazolinones, sulfonylureas, glyphosate or phosphinotricin (for example the "PAT" gene). The genes in question which impart the desired traits can also be present in combination with one another in the transgenic plants. Examples of "Bt plants" which may be mentioned are corn varieties, cotton varieties, soya bean varieties and potato varieties which are sold under the trade names YIELD GARD® (for example corn, cotton, soya beans), KnockOut® (for example corn), StarLink® (for example corn), Bollgard® (cotton), Nucotn® (cotton) and NewLeaf® (potato). Examples of herbicide-tolerant plants which may be mentioned are corn varieties, cotton varieties and soya bean varieties which are sold under the trade names Roundup Ready® (tolerance to glyphosate, for example corn, cotton, soya bean), Liberty Link® (tolerance to phosphinotricin, for example oilseed rape), IMI® (tolerance to imidazolinones) and STS® (tolerance to sulfonylureas, for example corn). Herbicide-resistant plants (plants bred in a conventional manner for herbicide tolerance) which may be mentioned include the varieties sold under the name Clearfield® (for example corn). Of course, these statements also apply to plant cultivars having these or still-to-be-developed genetic traits, which plants will be developed and/or marketed in the future.

The plants listed can be treated according to the invention in a particularly advantageous manner with the active compound mixtures according to the invention. The preferred ranges stated above for the mixtures also apply to the treatment of these plants. Particular emphasis is given to the treatment of plants with the mixtures specifically mentioned in the present text.

The good insecticidal and acaricidal action of the active compound combinations according to the invention can be seen from the examples which follow. While the individual active compounds show weaknesses in their action, the combinations show an action which exceeds a simple sum of actions.

A synergistic effect in insecticides and acaricides is always present when the action of the active compound combinations exceeds the total of the actions of the active compounds when applied individually.

The expected action for a given combination of two active compounds can be calculated as follows, according to S.R. Colby, Weeds 15 (1967), 20-22:

If

- 5 X is the kill rate, expressed as a percentage of the untreated control, when employing active compound A at an application rate of m g/ha or in a concentration of m ppm,
  - Y is the kill rate, expressed as a percentage of the untreated control, when employing active compound B at an application rate of  $\underline{n}$  g/ha or in a concentration of  $\underline{n}$  ppm and
- E is the kill rate, expressed as a percentage of the untreated control, when employing active compounds A and B at application rates of <u>m</u> and <u>n</u> g/ha or in a concentration of <u>m</u> and <u>n</u> ppm,

then

$$E=X+Y-\frac{X\cdot Y}{100}$$

15

If the actual insecticidal kill rate exceeds the calculated value, the action of the combination is superadditive, i.e. a synergistic effect is present. In this case, the actually observed kill rate must exceed the value calculated using the above formula for the expected kill rate (E).

After the desired period of time, the kill in % is determined. 100% means that all animals have been killed; 0% means that none of the animals have been killed.

# Use examples

#### Example A

# 5 Myzus persicae test

Solvent:

15

20

7 parts by weight of dimethylformamide

Emulsifier:

2 parts by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (Brassica oleracea) which are heavily infested by the green peach aphid (Myzus persicae) are treated by being dipped into the preparation of active compound of the desired concentration.

After the desired period of time, the kill in % is determined. 100% means that all aphids have been killed; 0% means that none of the aphids have been killed. The kill rates determined are calculated using Colby's formula (see page 39).

In this test, for example, the following active compound combination in accordance with the present application shows a synergistically enhanced activity compared to the active compounds applied on their own:

Table A1: Plant-damaging insects
Myzus persicae test

Active compounds	Concentration of active compound in ppm	Kill rate in % after 6 <sup>d</sup>	
	·	found*	calc.**
H <sub>3</sub> C H H <sub>3</sub> C O N CI CI N N N CF <sub>3</sub> (I-1-9)	4	15	
Br H <sub>3</sub> C CH <sub>3</sub> O CN (2-6) deltamethrin	0.16	50	
(I-1-9) + (2-6) deltamethrin (25:1)	4 + 0.16	80	57.5

\* found

= activity found

\*\* calc. .

= activity calculated using Colby's formula

Table A2: Plant-damaging insects
Myzus persicae test

Active compounds	Concentration of active compound in ppm	Kill rate in % after 6 <sup>d</sup>	
	•	found*	calc.**
$H_3C$ $H_3C$ $O$	0.8	0	
H <sub>3</sub> C CH <sub>3</sub> O CN CI F <sub>3</sub> C (2-12) lambda-cyhalothrin	0.032	0	
(I-1-9) + (2-12) lambda-cyhalothrin (25:1)	0.8 + 0.032	45	0

\* found

= activity found

\*\* calc.

= activity calculated using Colby's formula

## Example B

#### Phaedon cochleariae larvae test

5 Solvent:

7 parts by weight of dimethylformamide

Emulsifier:

2 parts by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (*Brassica oleracea*) are treated by being dipped into the preparation of active compound of the desired concentration and are populated with larvae of the mustard beetle (*Phaedon cochleariae*) while the leaves are still moist.

15

10

After the desired period of time, the kill in % is determined. 100% means that all beetle larvae have been killed; 0% means that none of the beetle larvae have been killed. The kill rates determined are calculated using Colby's formula (see page 39).

In this test, the following active compound combination in accordance with the present application showed a synergistically enhanced activity compared to the active compounds applied on their own:

Table B: Plant-damaging insects Phaedon cochleariae larvae test

Active compounds	Concentration of active compound in ppm	Kill rate in % after 3 <sup>d</sup>	
	V 40 00	found*	calc.**
$H_3C$ $H_3C$ $O$ $N$ $N$ $CF_3$ $CF_3$ $(I-1-9)$	0.16	0	
NC O H <sub>3</sub> C CH <sub>3</sub> CI CI (2-3) betracyfluthrin	0.16 ~	- 15	
(I-1-9) + (2-3) betracyfluthrin (1:1)	0.16 + 0.16	35	15

found

calc.

= activity found = activity calculated using Colby's formula

## Example C

# Plutella-xylostella test (resistant strain)

5 Solvent:

10

. 15

parts by weight of dimethylformamide

Emulsifier:

2 parts by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (*Brassica oleracea*) are treated by being dipped into the preparation of active compound of the desired concentration and are populated with caterpillars of the diamond back moth (*Plutella xylostella*, resistant strain), while the leaves are still moist.

After the desired period of time, the kill in % is determined. 100% means that all caterpillars have been killed; 0% means that none of the caterpillars have been killed. The kill rates determined are calculated using Colby's formula (see page 39).

In this test, the following active compound combination in accordance with the present application showed a synergistically enhanced activity compared to the active compounds applied on their own:

Table C1: Plant-damaging insects
Plutella-xylostella test (resistant strain)

Active compounds	Concentration of active compound in ppm	Kill rate in % after 6 <sup>d</sup>	
		found*	calc.**
H <sub>3</sub> C H H <sub>3</sub> C N	·	,	
CI N N N	0.0064	0	
`CF <sub>3</sub> (I-1-9)	y s		
NC CH <sub>3</sub>	0.0064		
CI CI		0	
(2-3) betracyfluthrin			
(I-1-9) + (2-3) betracyfluthrin (1:1)	0.0064 + 0.0064	35	0

\* found

= activity found

\*\* calc.

= activity calculated using Colby's formula

Table C2: Plant-damaging insects Plutella-xylostella test (resistant strain)

Active compounds	Concentration of active compound in ppm	Kill rate in % after 6 <sup>d</sup>	
		found*	calc.**
$H_3C$ $H_3C$ $O$ $N$ $CI$ $CI$ $CF_3$ $(I-1-9)$	0.0064	10	
H <sub>3</sub> C CH <sub>3</sub> O CN CI F <sub>3</sub> C (2-12) lambda-cyhalothrin	0.0064	0	
(I-1-9) + (2-12) lambda-cyhalothrin (1:1)	0.0064 + 0.0064	45	10

\* found

= activity found

\*\* calc..

= activity calculated using Colby's formula

#### Example D

# Spodoptera frugiperda test

5 Solvent:

7 parts by weight of dimethylformamide

Emulsifier:

2 parts by weight of alkylaryl polyglycol ether

To produce a suitable preparation of active compound, 1 part by weight of active compound is mixed with the stated amounts of solvent and emulsifier, and the concentrate is diluted with emulsifier-containing water to the desired concentration.

Cabbage leaves (*Brassica oleracea*) are treated by being dipped into the preparation of active compound of the desired concentration and are populated with caterpillars of the armyworm (*Spodoptera frugiperda*), while the leaves are still moist.

15

10

After the desired period of time, the kill in % is determined. 100% means that all caterpillars have been killed; 0% means that none of the caterpillars have been killed. The kill rates determined are calculated using Colby's formula (see page 39).

In this test, the following active compound combination in accordance with the present application showed a synergistically enhanced activity compared to the active compounds applied on their own:

Table D: Plant-damaging insects
Spodoptera frugiperda test

Active compounds	Concentration of active compound in ppm	Kill rate in % after 6 <sup>d</sup>	
		found*	calc.**
$H_3C$ $H_3C$ $H_3C$ $O$ $N$ $CF_3$ $CF_3$ $(I-1-9)$	0.032	75	
NC O H <sub>3</sub> C CH <sub>3</sub> CI CI (2-3) betracyfluthrin	0.032 -	- 0	
(I-1-9) + (2-3) betracyfluthrin (1:1)	0.032 + 0.032	100	75

\* found

= activity found

\*\* calc.

= activity calculated using Colby's formula